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Jeffrey Allen Willy 
THE UNFOLDED PROTEIN RESPONSE REGULATES HEPATOCELLULAR INJURY 
DURING THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS 
 
Non-alcoholic steatohepatitis (NASH), which is characterized by the induction of 
hepatocellular death and inflammation, is associated with the activation of cellular stress 
pathways such as the Unfolded Protein Response (UPR), an adaptive response to 
disruptions in endoplasmic reticulum (ER) homeostasis. Because the role of the UPR in 
the progression of liver disease is not well understood, we established an in vitro model 
to evaluate the role of the UPR in NASH and translated results to clarify disease 
progression in human liver biopsy samples.   
Treating HepG2 cells and primary human hepatocytes with saturated, but not 
unsaturated free fatty acids (FFAs), at physiologic concentrations induced hepatotoxicity 
by inhibiting autophagic flux. Saturated FFA treatment activated the UPR, including the 
transcription factors CHOP (GADD153/DDIT3) and NF-κB, leading to increased 
expression and secretion of cytokines such as TNFα and IL-8 that contributed to hepatic 
cell death and inflammation. Depletion of either CHOP or the RELA subunit of NF-κB in 
hepatocytes alleviated autophagy and cytokine secretion, resulting in enhanced cell 
viability and lowered inflammatory responses during exposure to saturated FFAs.     
We carried out next generation sequencing on cells deleted for either CHOP or 
RELA and identified IBTKα as a novel UPR member directly regulated by CHOP and 
NF-κB. In response to saturated FFAs, loss of IBTKα increased cell survival through 
lowered phagophore formation and reduced cytokine secretion. We also identified 
binding partners of IBTKα by immunoprecipitation and LC/MS, indicating that that IBTKα 
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is part of a protein complex which functions at ER exit sites to facilitate initiation of 
autophagy and protein secretion. Furthermore, we discovered that CHOP and RELA 
coordinately regulate proteasome activity through NRF2 as an adaptive response to an 
inhibition of autophagic flux following palmitate exposure. To validate our model, we 
utilized human liver biopsy samples and demonstrated up-regulation of the UPR 
coincident with accumulation of autophagy markers, as well as secretion of cytokines IL-
8 and TNFα in serum of NASH patients. Our study provides a mechanistic 
understanding of the roles of the UPR and autophagy in regulating saturated FFA-
induced hepatotoxicity at the cellular level.   
 
Ronald C. Wek, Ph.D., Chair 
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CHAPTER 1.  INTRODUCTION 
 
1.1 The pathogenesis of nonalcoholic fatty liver disease. 
Non-alcoholic fatty liver disease (NAFLD) includes a range of pathologies from 
simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which is characterized 
by fat accumulation in the liver, hepatic inflammation, and injury that can progress to 
cirrhosis [1, 2] (Fig 1-1). There is a strong correlation between body mass index (BMI) 
and the prevalence of NAFLD, and higher BMI has been associated with more severe 
liver disease; thus NAFLD is largely thought to be a result of over nutrition [3, 4]. Within 
the United States, approximately 1/3 of the population has some form of NAFLD, 
extending to over 3/4 of obese individuals [5]. Additionally, over half of patients with type 
2 diabetes in both the United States and Europe also have some form of NAFLD, 
suggesting a strong correlation between liver disorders, obesity, and metabolic disease 
[6].  
Although often thought to be relatively benign in the absence of inflammation, the 
manifestation of hepatic steatosis, or accumulation of fat in the liver, typically coincides 
with obesity, and excess fat in the adipose tissue has been suggested to lead to cellular 
dysfunction and the inability to properly store lipids [7]. During obese conditions, 
adipocytes containing excess fat secrete cytokines such as TNFα, which has been 
suggested to result in impaired insulin signaling [8]. Insulin resistance is a risk factor for 
NASH, contributing to excessive lipolysis within adipose tissues liberating free fatty acids 
(FFA) from triglycerides. Elevated serum FFAs play a key role in the pathogenesis of 
NASH, and therapies that enhance insulin sensitivity can ameliorate hepatic lipotoxicity, 
in part, by decreasing plasma FFAs. Saturated FFAs are more strongly implicated in 
hepatic lipotoxicity and are more potent inducers of hepatocyte death than unsaturated 
FFA [2, 9, 10]. Like other liver pathologies, inflammation due to cytokine activation and 
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release of alarmins from stressed and dying cells is considered to be central to disease 
progression, but the molecular pathways linking FFA lipotoxicity and inflammation in the 
progression of NASH are not yet well understood [11]. 
Current diagnosis and prognosis of NAFLD requires a combination of clinical 
assessment and invasive procedures to asses histopathology of the liver, which are 
combined into a scoring system referred to as the NAFLD Activity Score (NAS) [12, 13]. 
The current scoring system involves a combination of key parameters, such as steatosis, 
lobular inflammation, hepatocellular ballooning, and fibrosis, which are each evaluated 
on semi-quantitative scales that are integrated into a final NAS score ranging from in 
severity from 0 to 5. There is an urgent need to develop non-invasive approaches to 
monitor the progression of NAFLD towards NASH and fibrosis. Although sera-based 
biomarkers such as cleaved cytokeratin 18, TNFα, IL-8, and miR122 have been 
associated with NASH, these biomarkers are not accurate predictors of the severity of 
NASH, and liver biopsies are still relied upon for diagnosing disease progression of 
NAFLD [14-17].  
There are currently no FDA-approved drugs to reverse the hepatotoxicity 
associated with NASH. Mild cases of NAFLD can normally be managed by lifestyle 
modifications, which feature caloric restriction and exercise that can reduce both liver 
enzymes and BMI. However, these lifestyle changes cannot reverse liver fibrosis [18, 
19]. As a consequence, severe cases of NASH often require surgical intervention, such 
as bariatric surgery and even liver transplantation [20]. Importantly, it is not understood 
why only some NAFLD patients progress to more severe pathologies associated with 
NASH [21]. In order to improve diagnosis and treatment regimens, a better 
understanding of both the molecular mechanisms and etiology of pathogenesis of 
NAFLD/NASH is needed. 
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Figure 1-1. Pathogenesis of NAFLD. Nonalcoholic fatty liver disease begins with 
simple steatosis, or the presence of excessive fat in the liver. NAFLD can progress to 
nonalcoholic steatohepatitis, in which inflammation and scarring can begin to appear in 
addition to fat accumulation. Scar tissue can replace the hepatocytes during cirrhosis, 
and hepatocellular carcinoma can also arise either prior to or in the presence of cirrhotic 
tissue. 
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1.2 The Unfolded Protein Response in liver disease. 
Recent studies suggest that excess saturated FFAs disrupt endoplasmic 
reticulum (ER) function, activating the Unfolded Protein Response (UPR) that features 
transcriptional and translational regulation of genes that serve to restore cell 
homeostasis [9, 22]. Newly synthesized proteins slated for the secretory pathway enter 
the ER to be folded and modified prior to transfer to the Golgi, for eventual placement 
into membranes or secretion. Perturbation of cell homeostasis, such as an excess of 
unfolded proteins in the ER or alterations in lipid metabolism, results in ER Stress and 
activation of the UPR.   
The UPR is activated through three sensory proteins: Inositol Requiring 1α 
(IRE1α/ERN1), PKR-like ER kinase or PERK (EIF2AK3/PEK), and Activating 
Transcription Factor 6 (ATF6), which serve to sense perturbations in the ER [23]. 
Together these UPR sensors serve to induce gene expression networks to either 
alleviate stress damage and return the cell to homeostasis or alternatively proceed 
toward cell death (Fig 1-2). Each of these UPR sensors is a transmembrane protein 
embedded within the ER. During non-stressed conditions, the luminal portion of each 
sensory protein is bound to an ER chaperone protein called Binding immunoglobulin 
Protein (BiP/GRP78/HSPA5). However, upon ER stress, unfolded proteins are thought 
to titrate BiP from the luminal regulatory domains of UPR sensory proteins, contributing 
to their activation [24]. An alternative model for regulation of the UPR sensors suggests 
that unfolded proteins can bind directly to these luminal sequences, leading to sensor 
activation [25]. The consequent effect of either model is induction of the three branches 
of the UPR by disruptions of protein folding. 
ATF6 is present in two isoforms from separate genes, ATF6α and ATF6β, with 
ATF6α being the dominant transcriptional activator of the UPR, which we will refer to as 
simply ATF6. ATF6 is a transmembrane protein that is localized in the ER and can 
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contains two Golgi localization sequences in its luminal domain normally concealed by 
BiP [26]. During ER stress, BiP dissociates and ATF6 is transported from the ER to the 
Golgi, where proteolytic cleavage by site-1 (S1P) and site-2 (S2P) proteases occurs. 
The 50 kDa N-terminal portion of ATF6 that is positioned in the cytosol is then released 
from the Golgi and translocated to the nucleus. ATF6 then binds to ER stress response 
elements (ERSE) with the consensus sequence CCAAT-N9-CCACG located in the 
promoters of UPR target genes [27]. These target genes function in protein folding and 
ER-associated degradation (ERAD), which serves to eliminate problematic and unfolded 
proteins from this organelle via ubiquitination and proteasome-mediated degradation. 
The remaining C-terminal peptide of ATF6 in the Golgi is thought to be secreted, and 
may serve as a biomarker for ER stress. While the gene targets of ATF6β are unclear, 
recent literature has suggested that following cleavage of ATF6β, the N-terminal peptide 
will translocate to the nucleus and compete with and inhibit the adaptive ER stress 
response by ATF6α [28].   
There are also two gene isoforms of IRE1, designated IRE1α and IRE1β; 
however, only IRE1α is ubiquitously expressed [29]. The cytosolic portion of IRE1α 
(herein referred to as IRE1) has serine/threonine kinase and endoribonuclease domains. 
IRE1 is autophosphorylated following ER stress and BiP dissociation, and consequent 
IRE1 oligomerization activates the endoribonuclease functions [30, 31]. IRE1 
endoribonuclease cleaves cytosolic splicing of X-box Binding Protein 1 (XBP1) mRNA, 
which is then ligated by the RTCB catalytic subunit of tRNA ligase, leading to synthesis 
of an active XBP1s transcription factor [32, 33]. XBP1 target genes have been shown to 
be important for the adaptive response involved in remediating ER stress, including 
enhanced vesicular trafficking, secretion, and protein folding [30]. While XBP1 is thought 
to be cytoprotective, IRE1 also induces cell death signals independent of XBP1 splicing, 
such as the activation of c-Jun N-terminal kinase (JNK) through an interaction with 
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TRAF2 and the degradation of specific mRNAs, known as regulated IRE1-dependent 
decay (RIDD) [34, 35] 
PERK phosphorylates the α subunit of eIF2 (eIF2α~P), which serves to deliver 
the aminoacylated initiator to ribosomes during the initiation phase of protein synthesis. 
The eIF2α~P serves to repress global translation initiation, which decreases the influx of 
nascent proteins into the ER. Additionally, eIF2α~P leads to preferential translation of 
key stress response gene transcripts via bypass of inhibitory upstream open reading 
frames (uORFs) in the 5'-leader of the targeted mRNAs [36]. Preferentially translated 
genes include ATF4, encoding a transcriptional activator that functions to alleviate stress 
damage [23]. ATF4 also induces transcription of GADD34 (PPP1R15A), involved in 
feedback dephosphorylation of eIF2α~P, and CHOP (GADD153/DDIT3), a transcription 
factor that can trigger cell death during chronic stress. Both GADD34 and CHOP are 
also subject to preferential translation during eIF2α~P through uORFs, which as a 
consequence tethers expression of these UPR genes to continued ER stress [36]. 
The three arms of the UPR do not act independently, but rather coordinately 
regulate transcriptional expression in response to ER stress. For example, ATF6 
increases transcription of XBP1, resulting in increased XBP1 mRNA substrate for IRE1α 
to process into the functional XBP1s transcription factor [37]. In a similar manner, 
deletion of PERK in the liver of mice results in loss of ATF6 cleavage, as well as reduced 
XBP1 expression [38]. Furthermore, both ATF4 and ATF6 contribute to the 
transcriptional expression of CHOP in the liver during ER stress [39, 40]. Finally, 
although many of these transcription factors function as homodimers, they are also 
observed as heterodimers, such as ATF4-CHOP and ATF6α-XPB1s, allowing for the 
activation of quality control pathways, such as ERAD, to degrade of misfolded proteins 
[41-43].  
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Coordinated activation of the UPR activates biological pathways to expand the 
ER processing capacity, which as a consequence helps restore protein homeostasis. 
Key pathways that can assist with protein homeostasis include induction of autophagy, 
which transports damaged organelles and unfolded proteins to the lysosome for 
degradation, as well as ERAD to traffic problematic proteins to the proteasomes [43, 44]. 
Additionally, amino acid transporters and genes important for remediation of oxidative 
damage are upregulated to protect cells against negative metabolic events [45]. 
However, the UPR cannot always overcome the detrimental effects of cellular stresses, 
and continued induction of the UPR by chronic exposure to ER stress can instead 
activate cell death pathways and enhanced inflammation [46-48]. 
The UPR is activated in animal models of high fat diet and NASH, as well as liver 
biopsies from human patients of NAFLD [49, 50]. Because of the role of excess 
circulating FFAs in lipotoxicity in NAFLD, it has been suggested that FFAs play a role in 
activation of the UPR during the progression of simple steatosis to NASH [47]. Although 
the UPR is canonically activated during the accumulation of unfolded proteins, the liver 
plays a variety of roles in lipid metabolism and processing. Interestingly, both PERK and 
IRE1α can be activated by saturated FFAs even in the absence of their luminal domains, 
suggesting a non-canonical role for lipid-mediated activation within the trans-membrane 
domain of both kinases [51]. Additionally, saturated FFAs do not result in ATF6 cleavage 
and consequent downstream transcription regulation, indicating a discordant activation 
of the UPR [52]. While there is a strong correlation between activation of the UPR in 
progression of NAFLD, the direct role PERK and IRE1α pathways during the 
pathogenesis of simple steatosis to NASH remains unclear. 
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Figure 1-2. The Unfolded Protein Response.  ER Stress activates PERK, ATF6, and 
IRE1 to elicit changes in gene expression.  PERK phosphorylation of eIF2α results in a 
global inhibition of translation coincident with preferential translation of UPR-specific 
genes, ATF4 and CHOP, which serve to accommodate ER stress and determine cell 
fate.  ATF6 is released from the ER to the Golgi, where it is cleaved, and the N-terminal 
portion of ATF6 is subsequently translocated to the nucleus to induce gene expression.  
IRE1 acts as a riboendonuclease that facilitates cytoplasmic splicing of XBP1 mRNA, 
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enhancing the synthesis of active XBP1 that increases transcription of UPR target 
genes. Together, these three branches of the UPR: PERK activation, ATF6 cleavage, 
and IRE1-directing splicing of XBP1 mRNA- comprise the transcriptional and 
translational gene expression encompassing the UPR. 
 
1.3 CHOP regulates cell fate decisions. 
While the main goal of UPR activation is to restore cell to homeostasis following 
onset of ER stress, chronic stress can trigger a sustained and heightened UPR that 
instead results in cell death. This dual nature of the UPR has been referred to as a 
binary switch [53]. During the initial stages of ER stress, eIF2α~P allows for the inhibition 
of global translation to conserve energy as well as the preferential translation of ATF4, 
which is involved in the transcriptional expression of many genes important for cell 
adaptation and survival, including those serving as amino acid transporters and those 
contributing as antioxidants [54, 55]. Chronic activation of the UPR will instead result in 
increasing levels of eIF2α~P over an extended period that will induce high levels of 
CHOP transcriptional expression [56]. CHOP mRNA is also preferentially translation by 
eIF2α~P, and induced expression of this transcription factor plays a major role in cell 
death upon chronic ER stress. CHOP is suggested to directly or indirectly regulate 
expression of genes involved in directing cell death during ER stress, including 
repression of pro-survival gene BCL2 and activation of pro-death genes, such as DR5  
and PUMA [57]. While CHOP targeting of UPR gene transcription is generally thought to 
facilitate cell death, this can depend on cell type and the nature of the underlying ER 
stress.  
The role that CHOP plays in liver disease during exposure to high levels of 
saturated FFA is not well understood. Prior studies linked activation of CHOP to cell 
death, an important pathophysiological feature of NASH and cirrhosis [46, 58]. However, 
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the notion that CHOP plays a direct role in the progression of NASH is quite 
controversial in the literature. Evidence arguing against the role of a protective effect of 
CHOP during the progression of NASH has emerged from studies utilizing whole body 
CHOP knock-out mouse models fed a methionine-choline deficient diet, in which it was 
demonstrated that the absence of CHOP enhanced liver injury and inflammation. [59]. 
However, this was coincident with decreased macrophage and T-cell apoptosis due to 
the absence of CHOP in a whole animal, thus making it hard to discern the role of CHOP 
in the hepatocyte. Interestingly, a different group found that mice with whole body 
knockout of C/EBPβ, a paralog of CHOP, led to decreased CHOP levels and attenuated 
inflammation and hepatocellular injury when animals were fed a high fat diet [60].  
Because of technical reasons, liver specific CHOP knockout mice have not been 
created, resulting in controversial results utilizing whole animal knockout mice. 
Additionally, mouse models of NASH do not fully recapitulate the human disease state, 
making it increasingly difficult to understand the role of CHOP and inflammation at the 
level of hepatocyte during the progression of NASH.  
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Figure 1-3. Binary switch model. During the early stages of ER stress, eIF2α~P 
induces the preferential translation of ATF4, which then activates the transcriptional 
expression of genes involved in cell survival. If the cell does not return to homeostasis 
and eIF2α~P levels become hyperactived in levels and duration, induced transcription 
factor CHOP will activate the transcription of genes involved in cell death. 
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1.4 Phosphorylation of eIF2α induces preferential translation of IBTKα 
The central dogma of molecular biology features transcriptional expression of 
genes, followed by mRNA translation into protein. However, mRNA abundance does not 
necessarily correlate with protein expression, and recent literature has suggested that 
protein expression is primarily regulated by mechanisms of translational control [61]. A 
key protein involved in translational control is eIF2. During unstressed conditions, eIF2 is 
bound to GTP and amionacylated initiator tRNA, which then couples with the 40S 
ribosomal subunit. This 43S preinitiation complex associates with the 5’- “cap” of 
mRNAs, and then scans 5’ to 3’ along the mRNA until it couples the initiator tRNA to the 
start codon of the transcript. The large 60s ribosomal subunit will then join the initiation 
complex, allowing for translation elongation to ensue. During translation initiation, eIF2-
GTP will be hydrolyzed to eIF2-GDP, and the released eIF2-GDP will be then recycled 
to the GTP-bound form through the action of a guanine nucleotide exchange factor 
called eIF2B [36, 62].  
During cellular stresses, four different mammalian protein kinases, PERK, GCN2, 
PKR, and HRI can phosphorylate eIF2α at serine 51 [36, 63]. Once phosphorylated, 
eIF2α~P will act as an inhibitor for the eIF2-GDP to eIF2-GTP exchange by binding 
directly to eIF2B. The resulting lowered eIF2-GTP levels trigger a general reduction in 
translation initiation, coinciding with preferential translation of select mRNA transcripts, 
such as ATF4 and CHOP. As noted earlier, this preferential translation during eIF2α~P 
occurs through the actions of uORFs embedded within 5’-leader of the gene transcript 
[64, 65]. 
We recently identified the α isoform of inhibitor of Bruton’s tyrosine kinase 
(IBTKα) as being preferentially translated in response to and ER stress [66]. IBTKα 
contains four uORFs, of which uORF 1 and 2 are inhibitory and act to repress IBTKα 
protein expression. During ER stress, the inhibitory effects of uORFs 1 and 2 are 
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overcome and there is enhanced expression of IBTKα protein (Fig 1-4) [66]. While the 
biological functions of IBTKα are not yet understood, it is noted that IBTKα contains 
protein-protein interaction domains, including ankyrin repeats and the BTB/POZ domain, 
which is suggested to enable IBTKα to serve as a substrate adapter for the E3 ubiquitin 
ligase Cullin 3 [67, 68]. Furthermore, depletion of IBTKα from both mouse embryonic 
fibroblasts and HepG2 cells results in increased basal levels of cleaved caspase 3/7 
without any changes in cell division, suggesting that IBTKα serves an essential role in 
cell survival; however, the exact mechanism and substrates by which IBTKα regulates 
cell fate remain yet to be elucidated [66]. 
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Figure 1-4. Mechanisms of translational control of IBTKα. (A) The 40S small 
ribosomal subunit couples with eIF2-GTP and initiator tRNA. Once the 43S preinitiation 
complex is loaded onto the 5’- “cap” containing the eIF4F complex, the ribosome 
complex scan until an initiation codon, typically an AUG, is recognized. The 60S 
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ribosomal subunit is recruited, culminating in the formation of the 80S ribosomes that 
mediates translation elongation. During the process of translation initiation, the GTP 
bound to eIF2 is hydrolyzed to GDP, and eIF2 must be recycled to the eIF2-GTP 
through the actions of the guanine exchange factor eIF2B. (A) During non-stressed 
conditions when eIF2-GTP levels are high, ribosomes will initiate translation at the 
inhibitory uORF1 and uORF2, preventing translation initiation of the IBTKα coding 
sequence. (B) During stress and levels of high eIF2α~P, there will be low levels of eIF2-
GTP that aids bypass of uORF1 and uORF2. Scanning ribosomes instead initiate 
translation of the IBTKα coding sequence. 
 
1.5  Mechanisms of inflammation during metabolic disease 
 During the course of cellular injury, inflammation is a key biological response in 
which the secretion of factors such as chemokines and cytokines coordinate the repair of 
damaged tissues [69]. Metabolic diseases, ranging from type 2 diabetes to NAFLD, are 
chronic disorders and result in a low grade inflammatory state. Increased expression of 
pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) stemming from the 
adipocytes during both obesity and type 2 diabetes is a key feature of insulin resistance 
[8]. In addition to TNFα, a number of other cytokines, such as interleukins 6 and 1β (IL-6, 
IL-1β), are also induced during metabolic disorders such as obesity. These cytokines 
can bind to receptors on peripheral cells and activate key pathways: Nuclear Factor κB 
(NF-κB) and c-Jun N-terminal Kinase (JNK), acting as a cascade to further increase 
inflammation [70-72].  
Early studies focused on adipose tissue, but it has been shown that an 
increasing number of cell types play a pro-inflammatory role during the progression of 
metabolic disease [47, 73, 74]. For example, Kupffer cells, or resident macrophages, 
which represent nearly 10% of the liver, were shown to have enhanced activation and 
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release of cytokines such as TNFα, IL-12, IL-18, and IFNγ during the progression of 
NAFLD [75-77]. However, it is unclear whether Kupffer cell activation is mediated directly 
by excess FFAs or by a secondary effect due to circulating of alarmins, also called 
damage associated molecular patterns, from injured hepatocytes during NASH [11].  
Induction of inflammation is tightly regulated with the UPR during the progression 
of metabolic disease [22, 47, 78]. This is not entirely surprising, as both pathways are 
adaptive in nature. The UPR is initially activated to promote enhanced ERAD of mis-
folded proteins, clearance of damaged organelles, and also plays an important role 
directing anti-oxidant effects against toxic xenobiotics and FFAs [79, 80]. Similarly, the 
immune system is activated to promote wound healing and rid the body of external 
threats [81]. However, during prolonged activation, both the UPR and inflammation can 
become adverse to the host cells resulting in tissue damage [8, 9]. As noted above, the 
UPR can function in conjunction with key pro-inflammatory pathways, such as those 
directed by JNK and NF-κB [35, 82].  
The canonical JNK signal transduction pathway consists of induction of the 
activator protein-1 (AP-1) transcription factor via a cascade of protein kinases known as 
mitogen-activated proteins (MAPs). Environmental stresses, such as cytokines binding 
to cell surface receptors, activate the cascade of MAP kinases, eventually leading to 
nuclear localization of AP-1 and transcriptional expression of pro-apoptotic genes such 
as TNFα [83-85]. It has been shown that the UPR activates the JNK pathway through 
IRE1α association with TRAF2, an adapter protein for JNK. Hence, IRE1α is thought to 
be a critical mediator determining the balance between pro-survival, through 
downstream effects of XBP1s, and cell death responses, by activation of JNK and 
consequent TNFα expression (Fig 1-5) [35].  
 The canonical NF-κB signal transduction pathway consists of two transcription 
factors which dimerize, p50 and p65 (RELA), that are typically bound to the repressor 
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inhibitory kappa B alpha (IκBα) in the cytoplasm. When cytokines bind to specific cell 
surface receptors, such as tumor necrosis factor-receptor (TNF-R), the IKK complex will 
target IκBα for proteasomal degradation, allowing for NF-κB nuclear localization and 
transcriptional activation of target genes (Fig 1-5) [86-88]. It has been shown that the 
protein expression of IκBα is repressed by eIF2α~P during ER stress, allowing for 
nuclear localization of the p50/p65 dimer and consequent NF-κB pro-inflammatory 
response [82]. While NF-κB has been shown to be activated by saturated FFAs, it is 
unclear whether this regulatory scheme is due to canonical translational repression of 
IκBα [89]. Additionally, NF-κB activation is considered pro-survival for circulating B and T 
lymphotyctes [90], but the biological consequence of chronic NF-κB activation in 
hepatocytes has not yet been characterized during the progression of NAFLD. 
NAFLD is a condition in which the liver must adapt to excess nutrient intake, and 
when unresolved this adaptation becomes a chronic metabolic disorder with the potential 
for cellular injury. It is known that both ER stress and inflammation are significant 
features during the progression of metabolic diseases such as NAFLD. However, how 
ER stress and mediators such as NF-κB, along with secreted factors such as TNFα, 
contribute to lipotoxicity, liver injury, inflammation and progression from simple steatosis 
to NASH are not yet resolved [22].  
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Figure 1-5. NF-κB and JNK signal transduction pathways. Model describing the 
signal transduction pathways of NF-κB and JNK during metabolic stress. The 
heterodimer p65 and p50 that comprise the canonical NF-κB, translocate to the nucleus 
when the IκBα repressor is phosphorylated by the IKK complex and targeted for 
proteasome degradation in the cytosol. c-JUN and ATF2 transcription factors translocate 
to the nucleus following activation of the MAP kinase cascade. Both pathways are 
activated by unique cellular stresses, including cytokine activation, and induce the 
transcription of cytokines and chemokines. 
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1.6  The role of the Unfolded Protein Response in autophagy 
Autophagy is an essential pathway for the degradation and recycling of biological 
material within the cell, an important feature for establishing cellular homeostasis [91]. 
Upon induction of autophagy, double membrane vesicles called autophagosomes are 
responsible for trafficking damaged organelles and proteins to the lysosome for 
degradation by acid hydrolases, followed by release of degraded products into the 
cytosol, a process referred to as autophagic flux. Currently, 32 autophagy-related genes 
(ATG) have been identified in yeast, most of which have orthologues in higher 
eukaryotes with shared functions [92, 93]. These ATG proteins perform functions 
ranging from phagaphore initiation to facilitation of cargo loading into the lysosome (Fig 
1-6).  
Key proteins involved in formation of phagaphores are ATG1, for which there are 
two counterparts in higher eukaryotes: Unc-52-like kinase 1 (ULK1) and -2 (ULK2). Both 
ULK1 and ULK2 are known to associate with ATG13 and FIP200, and this complex 
localizes to and activates inducers of the initiating phagaphore such as the Beclin-1 
(ATG6) in the VPS34 complex [94]. Once phagophores are formed, autophagosomes 
elongate and load cargo. During this process, the mammalian ATG8 homolog (LC3) is 
incorporated into the membrane of the forming phagaphores. LC3 initially exists as a 
cytoplasmic form (LC3b-I), and must be proteolytically cleaved at the C-terminal domain 
by ATG4, followed by the conjugation of phosphatidylethanolamine by ATG5-ATG12-
ATG16L [95-97]. The lipidated form of LC3 (LC3b-II) facilitates loading of ubiquitinated 
cargo into autophagosomes through the interaction of proteins such as p62 [98, 99]. 
The location of autophagosome initiation has been suggested to occur at contact 
sites with the endoplasmic reticulum, designated ER exit sites (ERES), which are unique 
regions that are also central for assembly of COPII vesicles for secretion [100]. 
Formation of both autophagosomes and COPII vesicles at the ERES were shown to 
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require SEC proteins, such as SEC16, SEC31 and SEC13 [101, 102]. ER stress can 
alter SEC protein localization to the ERES, and disruptions in UPR signaling through 
liver specific PERK knockout lowers mRNA expression of multiple SEC family members 
[38]. While these results suggest a dynamic interplay between ER stress and SEC 
proteins, the biological implications have not been fully investigated. 
The UPR is thought to play an essential role in the progression of autophagy, 
including phagophore initiation, elongation, and autophagolysosome fusion [44]. While 
the UPR transcription factors ATF4 and CHOP were reported to contribute to the 
induction of key autophagy genes, it is not clear how the most proximal consequence of 
UPR activation, acute eIF2α-P, is linked to induction of autophagy and subsequent 
hepatocellular injury upon saturated FFA exposure [103]. However the fact that 
substitutions in eIF2α that block phosphorylation by PERK result in defective lipidation of 
LC3b and a consequent block in phagophore initiation [103], suggests that an unknown 
direct translational target of eIF2α-P is essential for the induction of autophagy during 
stress.  
It was shown that ER stress is a trigger for initiation of autophagy, and 
reclamation processes of autophagy are thought to be an important adaptation for cell 
survival [104, 105]. However, recent studies suggest that some ER stress agents induce 
an inhibition of autophagic flux, and this blockage in the autophagic process occurs 
coincident with cell death [106]. While the mechanisms of cell death are unclear, it has 
been suggested that induction of autophagy can thwart apoptosis, and inhibition of 
autophagic flux can instead contribute to necrotic phenotypes, such as necroptosis or 
autosis, which evokes an inflammatory response along with cell death [107-109]. Recent 
investigations have also shown an association with inhibition of autophagic flux and 
activation of ER stress in both mice fed high fat diets and liver biopsies of humans with 
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NASH, but it is not clear how this block in flux is occurring or if autophagy is playing an 
active role in cell death [50].  
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Figure 1-6. Steps in autophagy pathway. During autophagy initiation, a C-terminal 
peptide is cleaved by ATG4b, which results in formation of LC3b-I. The ATG5-ATG12-
ATG16L complex acts as an E3 ligase-like enzyme to add phosphatidylethanolamine to 
the C-terminal domain of LC3b-1, resulting in LC3b-II. LC3b-II binds to p62 and 
integrates into the membranes of the emerging phagaphores to facilitate cargo loading. 
ULK1/2 forms a complex with ATG12 and FIP200, which activates the Beclin1-ATG14L-
VPS34 complex, an essential step for initiation of phagaphores. Autophagosomes carry 
cargo to the lysosome and merge with endosomes, which carry acid hydrolases that are 
essential for degrading macromolecules. This pathway can be interrupted by 
pharmacological compounds, such as 3-methyladenine (3-MA), which blocks 
phagaphore initiation by inhibiting VPS34, or bafilomycin A1 or chloroquine, which 
blocks autophagic flux by collapse of the lysosomal pH gradient and preventing acid 
hydrolases from degrading material, respectively. 
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1.7   Proteasome functions in adaptive responses to injury 
 The half-live of proteins can range from minutes to days, and the degradation of 
proteins has been shown to be quite specific [110]. One of the main pathways for protein 
turnover within the cell is the ubiquitin-proteasome system (UPS). In the UPS, proteins 
are targeted to the proteasome for degradation through the addition of polyubiquitination 
on lysine 48 by specific enzymes called E1 ubiquitin-activating enzymes, E2 ubiquitin-
conjugating enzymes, and E3 ubiquitin-protein ligases [111]. While most proteins 
degraded through the proteasome require polyubiquitination, it is important to note that 
some proteins have been shown to be directed to the proteasome for degradation 
without the addition of ubiquitin [112].  
The proteasome is a multisubunit complex consisting of a 20S core subunit and a 
19S regulatory particle designed to break down cytosolic proteins into short peptides. 
Recognition of polyubiquitinated proteins is mediated by distinct subunits containing 
ubiquitin-like and ubiquitin-associated domains in the 19S regulatory particle [113]. 
Following substrate recognition, proteins are deubiquitinated in an ATP-dependent 
manner and translocated into the 20S core subunit for degradation [114]. The core 
subunit is comprised of two catalytic β-rings encoded by gene products PSMB1-7, as 
well as a side chain on either side called an α-ring encoded by genes PSMA1-7. The β 
rings 1, 2, and 5 possess proteolytic activity consisting of three key enzymatic features 
that cleave proteins, allowing for their breakdown to smaller peptide fragments. These 
enzymatic activities are (1) caspase-like, which cleaves after acidic residues, (2) trypsin-
like that cleaves after basic residues, (3) and chymotrypsin-like, which cleaves after 
hydrophobic residues, respectively [115, 116].  
Because the proteasome degrades mostly short-lived proteins, it is an important 
pathway for the rapid degradation of regulatory proteins such as IκB to facilitate the 
activation of NF-κB (Fig 1-5). Another key regulatory pathway controlled by the 
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proteasome is nuclear factor erythroid-derived 2-like 2 (NRF2), which is activated in 
response to oxidative damage. Under nonstressed conditions, NRF2 is targeted for 
proteasome degradation by kelch-like ECH-associated protein 1 (KEAP1); however, 
during certain cellular stresses, the KEAP1-NRF2 interaction is disrupted and NRF2 
localizes to the nucleus to promote transcriptional activation of stress response genes to 
alleviate oxidative damage, such as NQO1, GCLC and GSR. (Fig 1-7) [117]. Although 
the regulation of NRF2 by proteasome degradation is well understood, recent studies 
have shown that NRF2 also has an effect on proteasome activity and gene expression of 
proteasome subunits, such as PSMB5, in some but not all cell types [118, 119]. 
Furthermore, it was suggested that NRF2-dependent activation of genes encoding 
proteasome subunits plays a protective role, allowing for enhanced cell survival during 
the progression of ER stress [118].  
To understand the role of NRF2 in the progression of NASH, mice lacking NRF2 
(NRF2-/-) have been fed a long-term high fat diet. While these mice observed greater 
insulin sensitivity than WT counterparts fed a high fat diet, the NRF2-/- mice displayed 
increased liver damage and inflammation.  Interestingly, this phenotype was associated 
with enhanced activation of the UPR [120].  During ER stress and consequent activation 
of the UPR, the proteasome acts as a key degradation pathway to compensate for the 
accumulation of misfolded proteins through ERAD. During ERAD, chaperone proteins 
such as heat-shock protein 70 (HSP70) facilitate the substrate targeting and 
polyubiquitination of misfolded proteins through E3 ligases, allowing for proteasome 
targeting and degradation [121, 122].  NRF2 has been suggested to function as a 
downstream effector in the PERK pathway, in which NRF2 mutant cells exhibit 
decreased viability in response to ER stress agents [123]. While it has been suggested 
that PERK regulates phosphorylation of NRF2 and nuclear localization, other 
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mechanisms that involve alteration of KEAP1 regulation of NRF2 have not been 
explored [123]. 
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Figure 1-7. NRF2 signaling pathway. Under normal conditions, NRF2 is targeted for 
proteasome degradation by KEAP1, a cytoplasmic protein bound to actin. The KEAP1-
NRF2 interaction can be disrupted by either induction of protein kinases that 
phosphorylate NRF2 or proteins interacting with KEAP1. Both scenarios result in nuclear 
localization of NRF2 to allow it to bind with MAF proteins and transcriptional activation of 
target genes involved in antioxidant responses and enhanced proteasome activities.
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1.8  The role of NAFLD in hepatocellular carcinoma  
 Liver cancer, of which hepatocellular carcinoma (HCC) represents 70-85% of all 
subtypes, is the third leading cause of death due to cancer [124, 125]. While most cases 
of HCC are a result of chronic viral infection or alcoholic injury, the epidemiology of 
nearly half of all cases are unclear. Recent large scale studies have associated both 
obesity and NAFLD with an increased risk for HCC [126]. Interestingly, while fibrosis with 
progression to cirrhosis is often a key feature of HCC, recent literature has suggested 
that NAFLD might contribute to a small percentage (<20%) of non-cirrhotic HCC. This 
finding suggests that HCC might compromise the progression of NAFLD from simple 
steatosis to NASH, although the pathobiology and molecular mechanism remains 
unclear [127]. 
 While the molecular mechanisms describing the progression of NAFLD to HCC 
are not well understood, obesity and NAFLD are characterized as chronic inflammatory 
diseases. During obesity, TNFα is released from the adipose tissue and acts as a potent 
activator of both NF-κB and JNK, pathways that have both been implicated as pro-
oncogenic in multiple cancers [128]. Additionally, dysregulation of the mTOR pathway 
coincident with induction of autophagy has been observed in NAFLD [129]. Autophagy is 
upregulated in HCC, and inhibition of autophagy initiation enhances the efficacy of 
standard of care drugs [130]. Additionally, it was shown that the UPR is activated not 
only in NAFLD, but also in HCC, concurrent with increased CHOP expression in tumors. 
Deletion of CHOP in mice resulted in reduced tumor size and decreased pro-
inflammatory cytokines coincident with reduced macrophages [131]. While there is 
currently no direct evidence connecting the progression of NAFLD to HCC, the 
correlation between molecular pathways perturbed in the two disease states is 
significant.  
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1.9  CHOP regulates a biological network in the pathogenesis of NASH 
Recent studies have highlighted the importance of UPR activation and aberrant 
autophagy in the pathogenesis of NASH, but these reports rely on broad associations 
and lack mechanistic understanding regarding the roles of the UPR in the progression of 
simple steatosis to NASH [132, 133]. Chronic ER stress has long been associated with 
induction of cell death, but we propose that CHOP plays a direct role in both the 
hepatotoxicity and expression of secreted factors that induce death in the context of 
NASH. In this thesis, we will address the hypothesis that CHOP regulates NF-κB 
activation and consequent expression and TNFα, a cytokine shown to drive insulin 
resistance in metabolic disease. Additionally, we provide insight into why rodent models 
of NASH can be inadequate for recapitulating human liver disease. Determining the 
biological pathways and secreted factors directed by CHOP and the UPR will also help 
identify biomarkers and prognostic tools for liver disease and open new lines for 
research of therapies for NASH. Furthermore, whereas it has been suggested that FFAs 
are associated with an inhibition of autophagic flux, we propose a new mechanistic link 
between induction of ER stress, autophagy, and the resulting pathology associated with 
NASH [49, 134]. Together this line of investigation addresses a critical gap in our 
knowledge of NASH and the UPR by determining the mechanisms of hepatocyte death 
during saturated FFA exposure. We also explored the role of a novel UPR protein IBTKα 
in autophagy and provide a better understanding of the mode of death triggered by the 
UPR during metabolic stress. Finally, we explored the gene networks co-regulated by 
CHOP and NF-κB through next generation sequencing technology, and discovered that 
these two transcription factors coordinately regulate a biological network of activities, 
including proteasome activation through NRF2 as an adaptive response to a block in 
autophagic flux. Overall, these studies reveal new biological roles for both the UPR and 
CHOP in the hepatocyte during the pathogenesis of NAFLD. 
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CHAPTER 2.  EXPERIMENTAL METHODS 
 
2.1  Cell Culture and Measurements of Cell Viability 
HepG2 cells were purchased from ATCC and cultured in Minimum Essential 
Media from Life Technologies (Grand Island, NY) supplemented with 1 mM non-
essential amino acids, 1 mM sodium pyruvate, 2 mM glutaMAX, and 10% (v/v) fetal 
bovine serum at 37°C. Cells were seeded at 15,000 cells per 96-well plate or 3.7x106 
cells per 10 cm dish and treated with FFA in 1% BSA for the indicated times. FAAs were 
reconstituted first using warm isopropanol at 80 mM and then diluted to desired 
concentrations using media containing 10% FBS and 1% BSA. Following cell treatment 
with FFA for the indicated times, media was collected from cells and lactate 
dehydrogenase (LDH) [135]. Data was normalized to total LDH release by 10% triton X-
100. Conditioned media experiments was collected and subjected to centrifugation at 
200XG for 10 min prior to adding to recipient cells. Comparison of LDH activity in the 
donor conditioned medium before and after recipient cell incubation for 12 or 24 hours 
indicated that there was minimal contribution of LDH activity carried over from the 
conditioned medium. Furthermore, independent measurements of cell death were also 
carried out by imaging with calcein-AM, and these results supported key findings using 
LDH release. For inactivation studies, conditioned media supernatants were treated at 1 
hour using heat inactivation at 56°C, 10 µg/mL RNase A at 37°C, or 50 µg/mL 
Proteinase K at 37°C [136, 137].  Caspase 3/7 activity was measured using the Apo-
ONE homogenous caspase 3/7 assay from Promega (Madison, WI). Proteasome 
measurements were carried out using the chymotrypsin-like, trypsin-like, and caspase-
like promteasome-glo assays from Promega.   
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2.2  Generation of Stable Gene Knockdowns and Knockouts 
 Stable knockdown and control cells were generated by transducing HepG2 cells 
with lentivirus carrying shRNA from Sigma-Aldrich (St. Louis, MO) against shCHOP 
(TRCN0000364393 and TRCN0000007263), shATF4 (TRCN0000013574 and 
TRCN0000013575), shCXCL8 (IL-8) (TRCN0000058029 and TRCN0000058030), 
shTNFA (TNFα) (TRCN0000355911 and TRCN0000003757), shRELA 
(p65)(TRCN0000014687), shIRAK2 (TRCN0000431467 and TRCN0000418461), 
shIBTKα (TRCN0000082575 and TRCN0000082577), shATG5 (TRCN0000151963 and 
TRCN0000151474), shSEC16A (TRCN0000246017), shSEC31A (TRCN0000436177), 
shNFE2L2 (TRCN0000281950), shPSMB5 (TRCN0000003917), or control (SCH001). 
Cells transduced with lentivirus particles were selected for by resistance to 5 µg/mL 
puromycin and maintained for at least one week in the absence of puromycin prior to 
conducting experiments.  Stable knockouts were constructed by using a plasmid from 
Sigma-Aldrich expressing the guide RNA, Cas9, long terminal repeats, and puromycin 
for CHOP (HS0000185403, GGAAATCGAGCGCCTGACCAGG), PERK 
(Hs0000302986, AATTATCAGCACTTTAGATGGG), or IBTKα (HS0000392536, 
GCTTTGGATCTTGTAATGAAGG).  Stable N-terminal GFP-LC3b cells were constructed 
using a plasmid (EX-T0824-Lv103) from GeneCopoepia (Rockville, MD).  Following 
transduction, cells taking up virus were selected using 10 µg/mL puromycin and 
knockout cells were sorted for single cells using flow cytometry.   For the Gaussia 
luciferase assay, PSV40-gluc control plasmid from New Englad Biolabs (Ipswich, MA,) 
was transfected to cells and supernatant was used to measure secreted luciferase. 
 
2.3  Immunoblot Analysis and ELISAs 
 Protein lysates were collected, quantified using Pierce BCA Protein Assay Kit 
from Thermo Scientific (Waltham, MA), and separated by SDS-PAGE using 4-12% Bis-
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Tris gels. Following electrophoresis, proteins were transferred to nitrocellulose filters and 
blocked for 1 hr at room temperature with BLOTTO (Pierce). Filters were incubated 
overnight with antibodies that are listed in the supplement. Antibody preparations used in 
the immunoblot analyses include the following: Cell Signaling Technologies (Beverly, 
MA): eIF2α~P (#9721), eIF2α from (#5324), ATF4 (#11815S), GAPDH (# 2118S), TNFα 
(#6945), IκBα (#4812), p65 (#8242), p65~P (#3033), IRAK1 (#4504), IRAK2 (#4367), 
IRAKM (#4369), IRAK4 (#4363) CUL3 (2759S), ULK1 (8054S), PERK (5683), ATG5 
(2630S), S6K (9202S), P~S6K (9208S), calnexin (26795), cleaved caspase 3 (9664L), 
K48 (8081), K63 (5621), NRF1 (12381), NRF2 (12721); from Santa Cruz Biotechnology 
(Dallas, TX), CHOP (sc-7351) and LAMP2 (sc-18822); from Sigma-Aldrich, β-actin 
(A5441); from Novus, IL-8 (#H00003576-M05), LC3b (NB1002220), SEC16A 
(NB183016), IBTKα (NBP15033 & NBP188512), p62/SQSTM1 (H00008878-M01), ULK2 
(NBP133136), PSMB5 (NBP219983), and KEAP1 (NBP237431); from Thermo Scientific, 
calnexin (MA3-027); from Abcam (Cambridge, MA), SEC31A (AB8660), and Cathepsin 
D (AB97499); and from Abnova IRAK2 (#H00003656-M04). A 45-biomarker Multi-
Analyte Profile- Human InflammationMAP v 1.0 from Myriad RBM was used to measure 
cytokines, chemokines and acute-phase reactants, in conditioned media from HepG2 
cells treated with palmitate, oleate, or vehicle for 12 hours as well as human serum 
samples. Conditioned media experiments was collected and subjected to centrifugation 
at 200XG for 10 minutes. The fold change for the indicated cytokine in response to either 
FFA was normalized to vehicle. Human IL-8 and TNFα in the conditioned media were 
measured by using the R&D systems Quantikine ELISA kit D8000C and DTA00C, 
respectively. 
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2.4  Immunoprecipitation 
For immunoprecipitation analyses, cells were trypsinized, washed once with 
PBS, and flash frozen following a five min incubation on ice in a hypotonic lysis buffer 
containing 20 mM Hepes, 2 mM MgCl2, and 10% Glycerol.  Following a rapid thaw in a 
pre-warmed water bath, NaCl (150 mM final concentration) was added to cell 
suspensions on ice for five min, followed by a 15 min spin in a microfuge at 10,000xg.  
Supernatant was transferred to Protein G Dynabeads coated with the following primary 
antibodies: from Abcam, SEC16A (ab70722) and SEC31A (AB8660), from Novus, 
IBTKα (NBP188512), KEAP1 (NBP237431) and IgG rabbit and mouse control (3900 and 
5415).  After an overnight incubation in a cold room with continual rotation, beads were 
washed with a buffer solution containing 20 mM Hepes, 2 mM MgCl2, 10% glycerol, and 
150 mM NaCl.  Supernatant was removed and proteins associated with beads were 
eluted with either urea for LC/MS analysis, or with 1X SDS-PAGE buffer for immunoblot 
analysis. 
 
2.5  Cell Imaging 
For neutral lipid accumulation, cells were fixed with 1X Prefer from Anatech (San 
Diego, CA) this then stained with 1X LipidTOXTM Deep Red Neutral Lipid Stain and 10 
µg/mL Hoechst 33342, both from Life Technologies. For immunofluorescence, cells were 
fixed, permeabilized with 0.1% triton X-100 for 10 minutes, followed by overnight 
incubations with primary antibody in PBS containing 0.1% BSA, and finally a two hour 
incubation with the corresponding secondary Alexa Fluor conjugates and 10 µg/mL 
Hoechst (33342) from Life Technologies. For CLICK-IT reactions, 5 µM alexa-fluor 488 
alkyne was utilized from Life Technologies. To monitor viability, live cells were stained 
with 2.5 µM calcein-AM and 10 µg/mL Hoechst for 30 minutes prior to imaging. All 
images were acquired via spinning disk confocal microscopy using Perkin Elmer’s Opera 
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and quantified using Columbus (Waltham, MA). Three dimensional rendering of z-stack 
images was performed and quantified using Perkin Elmer’s Volocity. For electron 
microscopy, cells were concentrated by centrifugation, fixed in modified Karnovsky’s 
fixative, embedded in agar, post-fixed with 1% osmium tetroxide, dehydrated through an 
ascending series of ethanol, and processed and embedded in epoxy resin. 
Approximately one-micron thick toluidine blue stained sections, collected on glass slides, 
were prepared for ultrathin area selection. Ultrathin sections were collected on 200 mesh 
copper grids, counterstained with uranyl acetate and Sato’s Lead stain, and examined in 
a CM100 Philips transmission electron microscope (TEM). Digital images of 
representative tissue areas were captured for evaluation. 
 
2.6  Isolation of Primary Hepatocytes 
C57BL/6 female mouse and Sprague Dawley male rat primary hepatocytes were 
isolated by anesthetizing rodents with sodium-pentobarbital and perfusing the liver 
through the portal vein for 12-14 minutes with Perfusion Buffer (Gibco) followed by 10 
minutes L15 Buffer (Corning) containing collagenase and trypsin inhibitor (Worthington) 
at 42°C. Following digestion, livers were extracted from animals; digested cells were 
scraped and shaken from liver, followed by filtration and two spins at 50xG for 4.5 
minutes as described [138, 139]. Primary human hepatocytes were purchased from Life 
Technologies (lots Hu8203, Hu1743, and Hu1745). 
 
2.7  Polysome Profiling 
 HepG2 cells were treated for indicated times in the presence of vehicle, 
palmitate, thapsigargin, or oleate.  Following incubations, MEM containing 50 µg/mL 
cycloheximide was added for 10 minutes at 37°C prior to harvesting. Cells were washed 
with ice cold PBS containing 50 µg/mL cycloheximide and lysed, lysates were added to 
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10-50% sucrose gradient, subjected to centrifugation in a Beckman SW41Ti rotor for 2 
hours at 4°C at 40,000 rpm, and monitored by absorbance at 254 nm as described [140].  
ATF4, CHOP, and IBTKα mRNA levels were measured by qPCR in each of the seven 
collected fractions as described [66]. Firefly luciferase mRNA was spiked into to each 
fraction to facilitate normalization in the cDNA and qPCR analysis for the transcript 
measurements as described.  Data is represented as the percentage of transcript found 
in each fraction relative to the total for each mRNA, and a percentage change in large 
polysomes (fractions 5-7) with treatment relative to vehicle was measured. 
 
2.8  Measurements of mRNA by qPCR and Luciferase Activities 
RNA was isolated from cells using TRizol reagent (Invitrogen) and cDNA 
synthesis was carried out using TaqMan RT kit (Applied Biosystems) according to 
manufacturer’s instructions.  Primers used in the study are listed in Table 2-1. Transcript 
measurements were normalized to GAPDH for HepG2 and human primary hepatocytes 
or ACTB (β-actin) for mouse primary hepatocytes. HepG2 cells were transiently 
transfected using fugene 6 with the NF-κB reporter plasmid p5XIP10κB [141] and Renilla 
luciferase reporter plasmid for 24 hours, and the transfected cells were treated with 
palmitate or vehicle 12 hours, as indicated. Luciferase assays were carried out using the 
Dual-Luciferase reporter assay system (Promega) following the manufacturer’s 
instructions. 
 
2.9  RNA-seq and ChIP-seq analysis 
 For RNA-seq, wild type, CHOP-KO, and RELA-KO HepG2 cells were treated for 
12 hours with either vehicle or 600µM palmitate. RNA was isolated using TRizol reagent 
and sequencing was carried out on the Illumina platform at Covance Genomics. 
Sequencing reads were aligned to the hg19 human genome from UCSC using Tophat2, 
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and mapped reads were assembled and merged using the Cufflinks and Cuffmerge 
packages, followed by differential gene expression using Cuffdiff. For ChIP-seq 
experiments, wild type HepG2 cells were treated with 600µM palmitate for 12 hours and 
fixed using formaldehyde. DNA was isolated, pulled down with either CHOP or P~p65, 
and sequenced at Covance Genomics. Sequencing reads were aligned to the human 
genome from UCSC (hg19) using Homer, and peaks were called by comparing palmitate 
treated cells to untreated for each respective pull-down.  
 
2.10  Cell Migration Assay 
 Cell Migration assays were carried out using transwell boyden chambers with 5 
µM pores from Cell BioLabs (#CBA-105). Macrophage murine RAW 264.7 and human 
KG-1 cells were plated at 50,000 cells per insert in serum-free DMEM. Conditioned 
media from either control or knockdown cells was added to the lower wells and cells 
were allowed to migrate for six hours at 37°C. 
 
2.11  Statistical Analysis 
 Data are depicted as mean +/- standard deviation. Differences between multiple 
groups were analyzed using a one-way ANOVA followed by a post hoc Tukey HSD test 
to compare multiple groups. P values less than 0.05 were considered statistically 
significant and were indicated by "*", and treatment groups considered statistically 
significant from shCTRL treatment were indicated by the "#" sign unless otherwise 
noted. 
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CHAPTER 3.  RESULTS: CHOP links ER stress to NF-κB activation 
3.0 Introduction 
Free fatty acid induction of inflammation and cell death is an important feature of 
nonalcoholic steatohepatitis (NASH) and has been associated with disruption of the ER 
and activation of the Unfolded Protein Response (UPR). Following chronic UPR 
activation, the transcription factor CHOP triggers cell death; however, the mechanisms 
linking the UPR or CHOP to hepatoceullular injury and inflammation in the pathogenesis 
of NASH are not well understood. Using HepG2 and primary human hepatocytes, we 
found that CHOP induces cell death and inflammatory responses following exposure to 
saturated FFA by activating NF-κB through IRAK2 expression, resulting in secretion of 
cytokines IL-8 and TNFα directly from hepatocytes. Interestingly, CHOP/NF-κB signaling 
is not conserved in primary rodent hepatocytes. Our studies suggest that CHOP plays a 
vital role in the pathophysiology of NASH through induction of secreted factors that 
trigger inflammation and hepatocellular death via a signaling pathway specific to human 
hepatocytes. 
 
3.1 Saturated FFAs induce the UPR before lipotoxicity in hepatocytes 
Rodents are less sensitive to FFA-induced liver injury compared to humans [142-
144]. To determine if this species dependence is a property of hepatocytes, we 
measured the sensitivity of human hepatoma HepG2 cells and primary human, mouse, 
and rat hepatocytes to 24 hours of exposure to increasing concentrations of saturated 
FFA palmitate or stearate and unsaturated FFA oleate (Fig 3-1 A-C). Both saturated FFA 
triggered significant cell death in HepG2 and primary human hepatocytes (LC50 <600 
µM), whereas oleate did not induce cell death at concentrations up to 1000 µM (Fig 3-1 
D). By contrast, mouse and rat primary hepatocytes were less sensitive to palmitate and 
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completely resistant to cytotoxic effects of stearate (Fig 3-1 A-D). These results suggest 
that the species sensitivity to lipotoxic effects of saturated FFA is a property of the 
hepatocytes. 
Because HepG2 cells exhibited similar sensitivity to human primary hepatocytes 
following saturated FFA exposure, we used HepG2 cells to further explore the role of the 
UPR in hepatocellular stress responses to saturate FFA. As will be discussed later in the 
study, primary human hepatocytes also share many of the key features of UPR signaling 
that we discovered in the HepG2 cells. Hepatic steatosis characterized by intracellular 
accumulation of neutral lipid in hepatoctyes is a quintessential pathophysiologic feature 
of non-alcoholic fatty liver disease [1]. To determine if HepG2 cells accumulate neutral 
lipid in response to FFA exposure, we stained HepG2 cells with LipidTox
TM
. Both 
saturated and unsaturated FFA resulted in significant neutral lipid accumulation in 
HepG2 cells; however, the morphology was dissimilar (Fig 3-1 E). Palmitate and 
stearate resulted in diffuse cytoplasmic lipid staining, whereas cells treated with oleate 
formed polarized neutral lipid droplets without demonstrable toxicity. These results 
suggest that despite neutral lipid accumulation within cells, the inability of HepG2 cells to 
properly store neutral lipid upon exposure to saturated FFA is correlated with lipotoxicity, 
an idea supported by an earlier study [145]. 
To determine whether the UPR is activated prior to saturated FFA-induced cell 
death, we measured markers of the UPR during a time course of exposure to 
physiological concentrations of free fatty acids (600 µM) [146, 147]. Cell death first 
occurred from 12 to 24 hours after treatment with either palmitate or stearate (Fig 3-2 A-
B), which was preceded by activation of the UPR, with increased eIF2α~P and ATF4 
expression after just 3 hours of saturated FFA exposure and robust expression of CHOP 
at 12 hours (Fig 3-2 E-F). By comparison, oleate had a minimal effect on the UPR, with 
only modest transient induction of eIF2α~P and ATF4 levels, minimal CHOP expression, 
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and full cell viability (Figs 3-2 C and F). As a control, we also measured activation of the 
PERK pathway in response to tunicamycin, a well-characterized inducer of ER stress 
and the UPR. Tunicamycin activated the UPR in a manner similar to saturated FFA, but 
without any adverse effect on cell viability (Fig 3-2 D and F). To confirm that palmitate 
indeed activated the UPR, as opposed to cytosolic stresses that induce eIF2α~P, we 
measured IRE1-mediated splicing of XBP1 mRNA as well as GRP78 (BiP) levels by 
qPCR. There were significantly elevated spliced XBP1 and GRP78 mRNAs upon 
palmitate treatment of HepG2 cells, which were absent during oleate exposure (Fig 3-3 
A-B). The timing of the splicing of XBP1 mRNA mirrored that for increased CHOP mRNA 
levels, both of which followed a modest increase in ATF4 mRNA levels (Fig 3-3 C-D). 
However, there was no increase of ATF6 mRNA during treatment with palmitate (Fig 3-3 
E), supporting a previously reported discordant induction of the canonical branches of 
the UPR by saturated FFAs [52]. Oleate did induce ATF4 mRNA, consistent with the 
transient induction of this cytoprotective transcription factor (Fig 3-3 D). We conclude 
that saturated FFAs are potent inducers of the UPR in human hepatocytes prior to 
lipotoxicity. 
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Figure 3-1. Human hepatocytes are more sensitive to lipotoxicity than rodent 
hepatocytes. (A-C) Mouse primary hepatocytes (MPH), rat primary hepatocytes (RPH), 
HepG2 cells, and primary human hepatocytes (HPH) were treated with the indicated 
concentrations of palmitate, stearate, or oleate for 24 hours. Cell death was measured 
by LDH release. (D) LC50 values (µM) from LDH release assay were calculated in XLfit 
using four parameter curve fits. (E) HepG2 cells stained for neutral lipid accumulation 
using LipidTox Deep Red imaging, for up to 24 hours. Accumulation of neutral lipid in 
response to saturated FFAs was quantified by counting total spot counts in Perkin 
Elmer’s Columbus software package and normalized to vehicle. 
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Figure 3-2. Saturated but not unsaturated free fatty acids induce the UPR prior to 
lipotoxicity in human hepatocytes. (A-C) Cell death was measured by LDH release in 
HepG2 cells incubated with 600 µM palmitate, stearate, or oleate, for the indicated 
times. (D) Cell death was measured by LDH release in HepG2 cells incubated with 2 µM 
tunicamycin for the indicated times. (E-F) Immunoblot analysis of HepG2 lysates treated 
with 600 µM palmitate, 2 µM tunicamycin, 600 µM stearate, or 600 µM oleate for up to 
24 hours, as indicated. 
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Figure 3-3. The UPR is discordantly activated by saturated FFAs. (A-E) Changes in 
gene transcripts from HepG2 cells incubated with 600 µM palmitate or oleate for up to 24 
hours, as indicated. The XBP1s/t is a ratio of the spliced XBP1 mRNA relative to total 
XBP1 transcript.   
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3.2 Palmitate disrupts neutral lipid formation by localizing directly to the ER 
Because both saturated FFA, but not oleate, induced ER stress along with 
aberrant and diffuse neutral lipid staining proceeding cell death, we evaluated the 
ultrastructural features of HepG2 cells treated with FFA. HepG2 cells were treated with 
vehicle, palmitate, or oleate and observed by transmission electron microscopy (Fig 3-4). 
Similar to previous neutral lipid staining (Fig 3-1 E), ulltrastructural examination revealed 
that oleate treatment produced large neutral lipid droplets with a polarized cellular 
distribution. However, palmitate treatment led to crystalline structures in HepG2 cells 
without the appearance of polarized neutral lipid droplets (Fig 3-4). Finally, to address 
the intracellular localization of palmitate, HepG2 cells were treated with CLICK-IT® 
palmitic acid, azide. There was significant co-localization of the tagged palmitate with 
ER-associated proteins, PERK (27%) and calnexin (40%), which were visualized by 
immunofluorescence (Fig 3-5 A-B). These findings indicate that palmitate can localize 
directly to the ER in hepatocytes and that the neutral lipid droplets accumulating from 
palmitate have marked differences in character and distribution relative to neutral lipid 
accumulation after treatment with the non-toxic oleate. 
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Figure 3-4. Electron microscopy of HepG2 cells treated with FFAs. Electron 
microscopy showing ultrastructures of HepG2 cells treated with vehicle, oleate, or 
palmitate for the indicated times. 
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Figure 3-5. Palmitate localizes directly to the ER and PERK. (A-B) Spinning disk 
confocal images of CLICK-IT labeled palmitic acid azide tagged with alexa-fluor 488 
alklyne showing colocalization with the ER (calnexin) or PERK. The percent co-
localization of palmitate with calnexin and PERK are illustrated to the right of the images. 
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3.3 Palmitate inhibits initiation of global translation by PERK 
Activation of PERK and downstream eIF2α~P results in a global reduction in 
translation initiation. To address the effects of palmitate on translation, we performed 
polysome profiling using lysates prepared from HepG2 cells treated with vehicle, 
palmitate, oleate, or tunicamycin as a control for ER stress (Fig 3-6 A-C). Both palmitate 
and tunicamycin reduced large polysomes coincident with accumulation of monosomes, 
indicative of lowered global translation initiation. Oleate did not alter polysome profiles, 
consistent with its minimal effects on the UPR. To understand the role of PERK during 
translational repression following palmitate exposure, we treated HepG2 cells deleted for 
PERK by using CRISPR (PERK-KO) with palmitate and found that there was no 
reduction in large polysomes relative to vehicle, although there was some accumulation 
of monosomes (Fig 3-6 D). Additionally, PERK-KO cells were resistant to palmitate-
induced lipotoxicity coincident with decreased ATF4 and CHOP levels (Fig 3-6 E-F). 
These results suggest that activation of PERK due to saturated FFA palmitate is 
detrimental to hepatocyte survival. 
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Figure 3-6. Palmitate exposure results in an inhibition of global translation in a 
PERK-dependent manner. (A-C) Polysome profiles of lysates prepared from HepG2 
cells treated with vehicle, palmitate, oleate, or tunicamyicin for 12 hours. (D) Polysome 
profile of PERK KO HepG2 cells treated with either vehicle or palmitate for 12 hours. (E) 
Cell death of PERK KO HepG2 cells treated in the presence or absence of palmitate, as 
measured by LDH release,. (F) Immunoblot analysis of control and PERK KO HepG2 
cells after 12 h treatment of either vehicle or palmitate. 
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3.4 Knockdown of CHOP protects hepatocytes from lipotoxicity 
Elevated levels of CHOP are suggested to play a role in cell death during 
extended periods of ER stress [46, 58]. We addressed the role of CHOP in lipotoxicity by 
shRNA knockdown (shCHOP) in HepG2 cells. Control (shCTRL) and shCHOP cells 
were then measured for cell viability following exposure to palmitate for 24 hours. 
Palmitate treatment led to a modest loss of shCTRL cell viability as measured by LDH 
release after 12 hours of treatment, with about 50% lethality after 24 hours of palmitate 
exposure (Fig 3-7 A-B). By comparison, knockdown of CHOP provided for resistance to 
palmitate, as well as stearate treatment (Fig 3-7 C). Additionally, knockdown of ATF4 
(shATF4) in HepG2 cells did not alleviate saturated FFA induced cell death (Fig 3-7 D 
and Fig E). This finding is consistent with the notion that ATF4 has protective functions, 
whereas elevated CHOP levels facilitate cell death. 
During liver injury and NASH, release of both autocrine and paracrine factors is 
thought to play a role in disease progression [11]. We wished to address whether the 
sensitivity of human hepatocytes to saturated FFA can occur by release of paracrine 
factors. As illustrated in Fig 3-8 A, conditioned media prepared from shCTRL HepG2 
cells treated with palmitate for 3, 6, 12, or 24 hours was then applied to recipient 
shCHOP cells, which were incubated for an additional 24 hours and assayed for viability. 
The 12 hour conditioned medium led to over 20% death of the shCHOP cells, with 
approximately 40% of the cells succumbing to death following incubation with 24 hour 
conditioned medium (Fig 3-8 B). By comparison, conditioned medium from donor 
shCTRL cells treated with oleate or vehicle did not have a deleterious effect on survival 
of the recipient shCHOP cells (Fig 3-8 C). Additionally, we used another cell survival 
assay- calcein-AM, a cell-permeant dye that measures cell viability, to confirm that there 
was elevated death of the shCHOP cells treated with conditioned medium prepared from 
donor shCTRL cells incubated with palmitate for 24 hours (Fig 3-8 D). By comparison, 
 50 
 
direct palmitate treatment of shCHOP showed robust calcein-AM conversion, consistent 
with full viability.  
To address whether the secreted factor(s) in the conditioned medium that 
triggered death of recipient shCHOP cells is a polypeptide(s), the 12 and 24 hour 
conditioned media was treated with proteinase K, heat inactivation, or RNase A prior to 
incubation with the shCHOP cells for an additional 24 hours (Fig 3-8 E-F). Both 
proteinase K and heat treatments enhanced survival of the shCHOP cells, suggesting 
that CHOP induces expression and/or subsequent secretion of polypeptide(s) released 
from hepatocytes that can facilitate cell death during exposure to saturated FFA. 
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Figure 3-7. CHOP but not ATF4 is required for saturated FFA-induced 
hepatocellular death. (A) Control (shCTRL) HepG2 cells, or those knocked down for 
CHOP (shCHOP #1 and shCHOP #2), were treated with palmitate for 24 hours and cell 
death was measured by LDH release (top). The control and shCHOP cells were 
incubated for 12 hours in the presence (+) or absence (-) of 600 µM palmitate and the 
indicated proteins were measured by immunoblot (bottom). (B) shCTRL and shCHOP 
HepG2 cells treated with palmitate for indicated times and cell death was measured by 
LDH release. (C) Control (shCTRL) HepG2 cells, or those knocked down for CHOP 
(shCHOP #1 and shCHOP #2), were treated with stearate or oleate for 24 hours and cell 
death was measured by LDH release. (D) Control (shCTRL) HepG2 cells, or those 
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knocked down for ATF4 (shATF4 #1 and shATF4 #2), were treated with stearate or 
oleate for 24 hours and cell death was measured by LDH release. (E) Control (shCTRL) 
HepG2 cells, or those knocked down for ATF4 (shATF4 #1 and shATF4 #2), were 
treated with palmitate for 24 hours and cell death was measured by LDH release (top). 
Control and shATF4 cells were treated for 12 hours in the presence (+) or absence (-) of 
600 µM palmitate and the indicated proteins were visualized by immunoblot (bottom).   
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Figure 3-8. CHOP induces secretion of factors involved in hepatocyte death. (A) 
Diagram depicting conditioned media experiment.  Donor shCTRL HepG2 cells were 
incubated with for 600 µM palmitate or control vehicle for up to 24 hours, as indicated. 
The conditioned medium was then transferred to recipient shCHOP HepG2 cells for 24 
hours, and cell death was measured by LDH release. (B) Conditioned media was 
prepared from shCTRL HepG2 donor cells incubated for 3, 6, 12, or 24 hours in the 
presence of palmitate. Conditioned medium was then transferred to recipient shCHOP 
HepG2, and following incubation for 24 hour cell death was measured by LDH release. 
(C) Conditioned media was prepared from donor shCTRL HepG2 cells incubated for 3, 
6, 12, or 24 hours in the presence of vehicle or oleate. Conditioned medium was then 
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transferred to recipient shCHOP HepG2 cells, and following a 24 hour incubation cell 
death was measured by LDH release. (D) Conditioned media was prepared from donor 
shCTRL HepG2 cells incubated for 3, 6, 12, or 24 hours in the presence of vehicle. 
Conditioned medium was then transferred to recipient shCHOP HepG2 cells, and 
following a 24 hour incubation cell death was measured by LDH release. (E-F) 
Conditioned medium prepared from donor shCTRL cells cultured with palmitate for 12 or 
24 hours was treated with RNase A, heat inactivation, or proteinase K, and the treated 
conditioned medium was then incubated with recipient shCHOP cells for 24 hours. Cell 
death was measured by LDH release. 
 
3.5 CHOP induces an inflammatory response in hepatocytes in response to 
palmitate 
To determine the identity of the secreted factor(s), we profiled the conditioned 
media from Hep2G cells treated with vehicle, palmitate, or oleate by using an 
inflammatory biomarker screen (Myriad RBM). Secretion of several cytokines was 
induced in hepatocytes upon palmitate exposure, including IL-8, IL-7, TNFα, IL-4, and 
TNFR2 (Fig 3-9 A). To address the role of CHOP in the secretion of these factors, we  
carried out individual sandwich ELISAs in both control and shCHOP cells for IL-8 and 
TNFα, both of which have been shown to be increased in patients with NASH [17]. There 
were significant increases in the secretion of both IL-8 and TNFα in HepG2 cells treated 
with palmitate, which were sharply lowered in shCHOP cells (Fig 3-9 B-E). These results 
indicate that CHOP is required for secretion of pro-inflammatory factors from 
hepatocytes following exposure to saturated FFA. 
To determine the biological implications of the CHOP-dependent secreted 
factors, we knocked down IL-8 (CXCL8) and TNFα (TNFA) in HepG2 cells using shRNA 
(Fig 3-10 A-B). These knockdowns sharply reduced IL-8 and TNFα secreted 
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polypeptides (Fig 3-10 C-D). Whereas depletion of IL-8 did not rescue hepatocytes from 
palmitate-induced cell death relative to control cells (Fig 3-10 A), there was a sharp 
reduction in macrophage recruitment as measured by trans-well chemotaxis (Fig 3-10 
E). Depletion of TNFα rescued both the HepG2 cells from palmitate-induced cell death 
and prevented macrophage recruitment (Fig 3-10 B and F). These results indicate that 
CHOP is essential for secretion of factors involved in both hepatocyte cell death and pro-
inflammatory signals. To further address whether TNFα is a secreted factor by which 
CHOP signaling can drive cell death, 12 hour conditioned media from palmitate treated 
donor control or shTNFA cells was added to recipient shCHOP cells. Whereas 
conditioned media from the palmitate-treated control cells triggered almost 30% death of 
recipient shCHOP cells, conditioned media from the palmitate treated shTNFA cells only 
caused about 5% death (Fig 3-11 A).  These results indicate that TNFα is a major 
CHOP-dependent secreted factor responsible for hepatocyte cell death during exposure 
to saturated FFAs. 
Is TNFα sufficient to trigger death of shCHOP hepatocytes? To address this 
question, we added recombinant TNFα to the cultured medium of these cells in the 
presence or absence of palmitate. There was significant death of the shCHOP cells 
upon TNFα treatment only when added in combination with palmitate (Fig 3-11 B). By 
comparison, addition of recombinant IL-8 to the shCHOP cells did not have any adverse 
effect on cell viability. We conclude that induced secretion of TNFα is an important 
reason for the CHOP pathway eliciting hepatocyte death upon exposure to saturated 
FFAs. Furthermore, treatment of shCHOP cells with the combination of TNFα and IL-8, 
but neither alone, signaled macrophage migration, as judged by transwell chemotaxis 
(Fig 3-11 C). The requirement for both TNFα and IL-8 for the inflammatory response is 
consistent with our finding that knockdown of either was sufficient to thwart macrophage 
migration. 
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Figure 3-9. CHOP directs hepatocyte secretion of TNFα and IL-8 upon exposure to 
palmitate. (A) RBM Myriad biomarker panel measuring the indicated secreted factors 
from HepG2 cells treated with either palmitate or oleate for 12 hours. Values are 
normalized to vehicle treatment, and "#" indicates biomarkers were statistically 
significant relative to the oleate treatment group. (B-C) Sandwich ELISAs measuring IL-8 
and TNFα from conditioned media of shCTRL or shCHOP HepG2 cells treated with 600 
µM palmitate or oleate for 12 hours, or vehicle control. (D-E) HepG2 cells were treated 
with palmitate, oleate, or vehicle for the indicated numbers of hours. From these cells, 
levels of CXCL8 (IL-8) and TNFA (TNFα) mRNAs were measured by qPCR (left) and 
TNFα and IL-8 were measured by sandwich ELISA (right). 
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Figure 3-10. TNFα and IL-8 recruit inflammatory cells while only TNFα plays a role 
in hepatocellular viability. (A) Control (shCTRL) HepG2 cells, or those knocked down 
for IL-8 expression (shCXCL8 #1 and shCXCL8 #2), were treated with palmitate for 24 
hours and cell death was measured by LDH release (top). The indicated proteins were 
measured by immunoblot using lysates prepared from control and shCXCL8 cells 
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incubated for 12 hours in the presence (+) or absence (-) of 600 µM palmitate (bottom). 
(B) Control HepG2 and those depleted for TNFα (shTNFA #1 and shTNFA #2) were 
treated with palmitate for 24 hours and cell death was measured by LDH release (top). 
Immunoblot analyses were also carried out to measure the indicated proteins in the 
shCTRL and shTNFA cells treated with palmitate for 12 hours (+) or vehicle (-) (bottom). 
(C-D) Sandwich ELISAs for shCXCL8 and shTNFA cells depicting repressed secreted 
polypeptides. (E-F) Cell migration assay for KG-1 cells using conditioned media 
prepared from shCTRL, shCXCL8, or shTNFA cells treated with either vehicle or 
palmitate for 12 hours.   
 59 
 
 
Figure 3-11. Palmitate requires TNFα for hepatocellular death. (A) Direct treatment 
indicates cell death of shCHOP cells incubated with palmitate for 24 hours. Alternatively, 
donor shCTRL or shTNFA HepG2 cells were incubated with palmitate for 12 hours. 
Conditioned medium was then applied to recipient shCHOP cells for 24 hours, and cell 
death was measured by LDH release. (K) The shCHOP HepG2 cells were treated with 
vehicle, 600 μM palmitate, 10 ng/ml TNFα, 1000 ng/ml IL-8, or a combination of the 
recombinant proteins and palmitate for 24 h, as indicated. Cell death was measured by 
LDH release. (L) Conditioned medium was  prepared from donor shCHOP HepG2 cells 
after 12-h treatment with vehicle or palmitate, and 10 ng/ml TNFα and/or 1000 ng/ml IL-8 
was added to indicated conditioned medium before performing the KG1 cell migration 
assay.  
 60 
 
3.6 CHOP activates NF-κB during palmitate exposure 
Transcriptional expression of CXCL8 (IL-8) and TNFA (TNFα) are known targets 
of NF-κB, so we determined whether CHOP serves to activate NF-κB in response to 
saturated FFA. Elevated eIF2α~P can reduce synthesis of the IκBα, which can 
contribute to NF-κB activation [148]. Indeed IκBα levels were reduced after treatment 
with the saturated FFA, which were undeterred in the CHOP-deficient cells (Fig 3-12 A). 
In fact, IκBα levels were lowered basally in shCHOP cells, contributing to further 
reductions in IκBα during treatment with palmitate. Next we measured phosphorylation of 
the p65 subunit of NF-κB at serine 536, which facilitates NF-κB targeting to the nucleus 
and transcriptional activation [87]. Phosphorylation of p65 was induced in shCTRL 
HepG2 cells by palmitate, but not in shCHOP cells (Fig 3-12 A). Furthermore, 
phosphorylated p65 localized to the nucleus upon palmitate treatment (Fig 3-12 B). 
Finally, transcriptional activity of a NF-κB-responsive reporter was induced 3-fold upon 
treatment of HepG2 cells with palmitate (Fig 3-12 C). By comparison, shCHOP cells 
showed minimal NF-κB activity. Collectively these results indicate that CHOP is required 
for induced NF-κB transcriptional activation in response to saturated FFA. 
 We next investigated the requirement for CHOP in activation of canonical NF-κB 
target genes CXCL1, CXCL2, and CXCL3, as well as CXCL8, and TNFA (Fig 3-13). For 
each of these NF-κB-target genes, CHOP-depletion blocked increased mRNA levels in 
response to palmitate to the same or greater extent as knockdown of RELA, encoding 
the p65 subunit of NF-κB. These results suggest that CHOP is not only required for NF-
κB activation, but also plays a central role in secretion of pro-inflammatory cytokines 
following palmitate exposure. 
 To address whether the decrease in cytokine gene expression in shCHOP and 
shRELA cells affects inflammation, we measured macrophage chemotaxis using 12 hour 
conditioned media from HepG2 cells treated with palmitate (Fig 3-14 A). Whereas, 
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conditioned medium prepared from shCTRL HepG2 cells enhanced migration of human 
KG-1 cells, there was a marked reduction in macrophage migration when the 
conditioned medium was prepared from cells depleted for either CHOP or p65. 
Knockdown of p65 (shRELA) in HepG2 cells also prevented cell death following 
palmitate exposure (Fig 3-14 B-C). However, conditioned media from donor shCTRL 
HepG2 cells triggered death of recipient shCHOP and shRELA cells (Fig 3-14 D), 
supporting the idea that both CHOP and p65 are required for the activation and 
secretion of TNFα, but are not the downstream effector pathway resulting in cell death. 
These results indicate that CHOP is required for the activation of NF-κB-dependent 
secreted factors that play a role in both cell death and inflammation. 
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Figure 3-12. CHOP is required for activation of NF-κB in hepatocytes treated with 
palmitate. (A) shCTRL or shCHOP HepG2 cells were treated with either vehicle (-) or 
palmitate (+) for 12 hours, followed by immunoblot analyses that measured the indicated 
proteins. (B) Nuclear localization of total and phospho-p65 was measured by 
Immunofluorescence microscopy in HepG2 cells that were treated with palmitate or 
vehicle. In parallel, Hoeschst staining was used to visualize nuclei, and the nuclear 
staining and p65 imaging was merged. (C) An NF-κB reporter plasmid was transiently 
transfected into shCTRL and shCHOP HepG2 cells, which were then treated with either 
vehicle or palmitate for 12 hours and reporter firefly luciferase activity was measured and 
normalized to Renilla luciferase. 
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Figure 3-13. CHOP and NF-κB are both required for a subset of cytokine and 
chemokine gene expression. (A-E) Levels of the indicated gene transcripts were 
measured by qPCR in HepG2 cells that were treated with palmitate for 12 hours, or 
vehicle.  
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Figure 3-14. CHOP and NF-κB are both required for cell death and macrophage 
recruitment. (A) Cell migration assays were carried out for 6 hours using KG-1 cells 
incubated with conditioned media prepared from HepG2 cells expressing shCTRL, 
shCHOP, or shRELA that were treated with palmitate for 12 hours, or vehicle. (B) The 
shCTRL and shRELA HepG2 cells were treated with either vehicle (-) or palmitate (+) for 
12 hours, and the indicated proteins were measured by immunoblot analyses. (C) 
HepG2 cells expressing shCTRL, shCHOP, or shRELA were cultured in palmitate for 24 
hours and cell death was measured by LDH release. (D) Conditioned medium was 
prepared from donor shCTRL cultured in palmitate for 12 hours and applied to recipient 
shCTRL, shCHOP, or shRELA HepG2, and following a 24 incubation cell death was 
measured by LDH release. 
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3.7 CHOP activates NF-κB in part through IRAK2 signaling 
CHOP protein is fully induced in shRELA cells in response to palmitate, further 
supporting the idea that CHOP functions upstream of NF-κB (Fig 3-14 B). We proposed 
that an IRAK protein, previously linked to NF-κB signaling [149], may function 
downstream of CHOP in its activation of NF-κB. There are four human IRAK isoforms, 
IRAK1, IRAK2, IRAKM, and IRAK4, and we measured the mRNA and protein for each in 
the shCTRL and shCHOP HepG2 cells treated with palmitate. IRAK2 mRNA was the 
only isoform induced following exposure to palmitate, and was also the only isoform for 
which the mRNA and protein was substantially lowered by shCHOP (Fig 3-15 A-B). It is 
noted that the IRAK2 protein was not significantly induced in response to palmitate, 
despite the robust increase in IRAK2 mRNA. This suggests that CHOP serves to 
enhance IRAK2 mRNA, which is required to maintain IRAK2 protein levels during the 
saturated FFA stress. By contrast, knockdown of ATF4 did not affect induction of IRAK2 
mRNA in response to palmitate (Fig 3-15 B). These results suggest that CHOP, but not 
ATF4, is required for IRAK2 expression following UPR activation by saturated FFA. 
 To determine the effects of IRAK2 on NF-κB following palmitate exposure, we 
knocked down IRAK2 in HepG2 with two different shRNAs and treated the cells with 
palmitate (Fig 3-16 A). Depletion of IRAK2 significantly lowered phosphorylation of p65 
at serine 536 following palmitate exposure despite elevated CHOP levels, suggesting 
that IRAK2 is a CHOP-dependent protein kinase essential for NF-κB activation in 
hepatocytes following exposure to palmitate. Next we carried out a chemotaxis assay 
with the KG-1 cells utilizing the conditioned media from either shCTRL or shIRAK2 cells, 
and determined that depletion of IRAK2 impaired macrophage migration (Fig 3-16 B). 
Because we previously showed that IL-8 and TNFα are both required for macrophage 
chemotaxis following palmitate treatment, we measured their mRNA levels by qPCR in 
shCTRL and shIRAK2 cells (Fig 3-16 C-D). There was a sharp reduction in CXL8 (IL-8) 
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and TNFA (TNFα) transcripts in shIRAK2 cells, consistent with lowered NF-κB activity. 
These results indicate that IRAK2 contributes to the initiation of an inflammatory 
response stemming from hepatocytes through activation of NF-κB. 
To address the role of IRAK2 depletion on hepatocyte lipotoxicity, we evaluated 
cell death by LDH release in shIRAK2 cells following exposure to palmitate. Knockdown 
of IRAK2 rescued HepG2 cells from palmitate-induced cell death (Fig 3-16 E). 
Furthermore, to explore whether IRAK2 is required for the secretion of factors involved in 
hepatocyte cell death, we measured the viability of recipient shCHOP cells treated with 
conditioned media prepared from donor shIRAK2 cells exposed to palmitate (Fig 3-16 
F). Knockdown of IRAK2 thwarted the ability of the conditioned medium to trigger death 
of the recipient shCHOP cells, supporting the idea that IRAK2 facilitates NF-κB-directed 
secretion that can trigger hepatocyte death. 
CHOP is directly or indirectly required for induction of IRAK2 mRNA in response 
to palmitate treatment, as well as for sustained IRAK2 protein levels (Fig 3-15 A-B and 
3-16 A).  However, there was no reproducible increase in the levels of IRAK2 protein in 
response to saturated FFAs. There was a sharp reduction in global translation in HepG2 
cells treated with palmitate for 12 h (Fig 3-6 A). Lowered global initiation of protein 
synthesis, as judged by diminished polysomes coincident with increased monosomes, 
was also observed after 6 h of treatment with saturated FFAs (Fig 3-17 A). ATF4 and 
CHOP mRNAs are preferentially translated in response to eIF2α~P, which can be 
visualized by the shift of either transcript from monosome to polysome fractions upon 
palmitate treatment (Fig 3-17 B-C). By contrast, in HepG2 cells treated with palmitate for 
either 6 or 12 h, the distribution of IRAK2 mRNA was largely unchanged between the 
monosome and polysome fractions compared with nonstressed conditions (Fig 3-17 D-
E). Note that in nonstressed conditions, the majority of IRAK2 transcripts were in the 
largest polysome fraction, fraction 7, whereas upon exposure to palmitate for either 6 or 
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12 h, there was a shift of IRAK2 mRNA toward smaller polysome fractions. This 
distribution of IRAK2 mRNA within polysome fractions suggests that there is lowered 
IRAK2 mRNA translation in response to eIF2α∼P and exposure to saturated FFAs, 
which provides an explanation for why IRAK2 protein was not significantly enhanced 
during palmitate treatment despite there being increased IRAK2 mRNA. Together these 
results indicate that CHOP is required for hepatocytes to sustain elevated levels of 
IRAK2 protein upon exposure to saturated FFAs. Elevated levels of IRAK2 proteins are 
suggested to be required for activation of NF-κB and subsequent increased expression 
and secretion of cytokines, such as TNFα and IL-8, which are involved in cell death and 
inflammation. However, high levels of IRAK2 protein are not sufficient to induce NF-κB, 
suggesting that additional signals emanating from hepatocyte stress induced by 
saturated FFAs also contribute to the observed activation of NF-κB. 
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Figure 3-15. CHOP is required for IRAK2 expression. HepG2 cells expressing 
shCTRL or shCHOP were cultured in the presence (+) or absence (-) of palmitate. (A) 
The indicated proteins from these cells were then measured by immunoblot analyses. 
(B) Levels of the indicated isoforms of IRAK mRNAs expressed in these cells were 
measured by qPCR. 
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Figure 3-16. IRAK2 is required for palmitate-induced hepatotoxicity and cell 
migration. (A) The shCTRL HepG2 cells, or those expressing shIRAK2 were treated 
with either vehicle (-) or palmitate (+) for 12 hours, and the indicated proteins were 
measured by immunoblot analyses. (B) Cell migration assay for KG-1 cells using 
conditioned media prepared from shCTRL or shIRAK2 HepG2 cells that were treated 
with either vehicle or palmitate for 12 hrs. (C-D) The mRNA levels of CXCL8 (IL-8) and 
TNFA (TNFα) were measured by qPCR in shCTRL and shIRAK2 HepG2 cells treated 
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with palmitate for 12 hours or vehicle. (E) HepG2 cell expressing shCTRL or shIRAK2 
were cultured in the presence of palmitate for 24 hours and cell death was measured by 
LDH release. (F) Direct treatment indicates cell death as measured by LDH release of 
shCHOP cells incubated with palmitate for 24 hours.  Alternatively, donor shCTRL or 
shIRAK2 HepG2 cells were incubated with palmitate for 12 hours. The conditioned 
medium was then applied to recipient shCHOP cells for 24 hours, and cell death was 
measured by LDH release. 
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Figure 3-17. IRAK2 exhibits reduced translation following eIF2α~P. (I) Polysome 
profiles of lysates prepared from HepG2 cells treated with palmitate or vehicle for 6 h. 
(J–L) Fractions were collected by the sucrose gradient analyses prepared from the 
HepG2 cells treated with palmitate or vehicle for 6 h, and the relative levels of the ATF4, 
CHOP, and IRAK2 mRNA were then determined by qPCR for each fraction. The 
percentage of the total levels for the indicated gene transcript in each of the seven 
fractions is illustrated. The percentage change in the indicated mRNA association with 
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large polysomes (fractions 5–7) in response to palmitate is indicated above the 
polysome. For example, ATF4 showed a 38% increase in transcript levels into fractions 
5–7 during palmitate treatment. (M) A similar analysis was carried out for changes in 
IRAK2 mRNA in polysome fractions in HepG2 cells treated with palmitate or vehicle for 
12 h.   
 
3.8 CHOP activates NF-κB in human but not mouse primary hepatocytes 
 Rodent models of NASH are often lacking in their ability to mimic the human 
disease [142, 143]. Earlier we showed differential affects between rodent and human 
hepatocytes with regards to lipotoxicity, suggesting a cell autonomous component for the 
species difference (Fig 3-1 A-D). Next we determined if there were also differences in 
NF-κB signaling and expression of cytokines following exposure to saturated FFA. 
Following 12 hours treatment with palmitate, mouse primary hepatocytes lacked the 
ability to activate NF-κB as judged by p65 phosphorylation of serine 536 (Fig 3-18 A). 
There was no induction of IRAK2 mRNA in the mouse primary hepatocytes upon 
palmitate exposure and minimal IRAK2 protein expression (Fig 3-18 A). Although the 
UPR was activated in the mouse primary hepatocytes, as indicated by elevated CHOP 
levels, the inability of primary mouse hepatocytes to activate NF-κB resulted in no 
induction of TNFA mRNA (Fig 3-18 B). Because mice do not express CXCL8, we 
measured mRNA levels for CXCL1 (KC) and CXCL2 (MIP-2), murine paralogs for IL-8, 
and found that only MIP-2 was modestly induced following palmitate exposure (Fig 3-18 
B). These results indicate that although the UPR can be activated in mouse hepatocytes 
exposed to palmitate, downstream NF-κB signaling appears to be unaffected by 
saturated FFA. 
 In contrast to primary mouse hepatocytes, we found that palmitate treatment of 
primary human hepatocytes led to activation of NF-κB, in combination with induction of 
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the UPR as supported by induction of CHOP mRNA and protein (Fig 3-19 A-B). 
Importantly, palmitate treatment of human primary hepatocytes increased p65 
phosphorylation of serine 536 (Fig 3-19 A), along with increases in IRAK2, TNFA (TNFα) 
and CXCL8 (IL-8) mRNAs (Fig 3-19 B). To understand the functional consequence of 
NF-κB activation in the primary cells, we carried out a chemotaxis assay with both 
human KG-1 and murine RAW cells utilizing conditioned media from HepG2, human 
primary hepatocytes, and mouse primary hepatocytes.  We found that only HepG2 and 
human primary hepatocytes elicited migratory effects on the macrophage cell lines (Fig 
3-20 A). Finally as noted earlier, saturated FFA triggered death of human primary 
hepatocytes, but not rodent hepatocytes (Fig 3-1 A-B). Together these results support 
the model that in human hepatocytes both CHOP and NF-κB are activated by palmitate, 
leading to production of TNFα and IL-8 that facilitate cell death and/or inflammatory 
responses. 
 Because there were such significant differences between NF-κB activation in cell 
death and inflammation in human primary hepatocytes compared to murine hepatocytes, 
we wanted to determine if secreted factors from human hepatocytes could trigger death 
of mouse hepatocytes. Conditioned media was prepared from donor shCTRL HepG2 
cells treated with either vehicle or palmitate and applied to recipient mouse primary 
hepatocytes (Fig 3-20 B). There was only a modest increase, albeit significant, in mouse 
hepatocyte death with the palmitate containing conditioned media relative to control. 
Consistent with our earlier findings, palmitate treatment alone did not appreciably affect 
the viability of mouse hepatocytes. Finally, we prepared conditioned medium from donor 
mouse hepatocytes treated with palmitate, which was applied to shCTRL and shCHOP 
HepG2 cells. There was less death of these human hepatocytes than when palmitate 
alone was applied to the media (Fig 3-20 B). These results suggest that in addition to not 
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inducing NF-κB activity and secretion of target cytokines upon exposure to saturated 
FFA, mouse hepatocytes lack sensitivity to respond to these regulatory signals. 
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Figure 3-18. NF-κB is activated in HepG2 cells but not mouse primary hepatocytes 
following palmitate exposure. (A) Human HepG2 cells and mouse primary 
hepatocytes (MPH) were treated with palmitate for 12 hours, or vehicle, and the 
indicated proteins were measured by immunoblot analyses (Top). IRAK2 antibody from 
Abnova was used in the immunoblot analysis (see Fig S3A). In parallel, IRAK2 mRNA 
was measured by qPCR in the HepG2 and mouse hepatocytes treated with palmitate for 
12 hours (Bottom). (B) Levels of the indicated mRNAs were measured in mouse primary 
hepatocytes treated with palmitate for 12 hours.   
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Figure 3-19. NF-κB is activated in primary human hepatocytes following palmitate 
exposure. (C) Human HepG2 cells and human primary hepatocytes (HPH) were treated 
with palmitate for 12 hours, or vehicle, and the indicated proteins were measured by 
immunoblot analyses (Top). Furthermore, IRAK2 mRNA was measured by qPCR in the 
HepG2 and human hepatocytes (HPH) treated with palmitate for 12 hours (Bottom). (D) 
The indicated mRNA levels were measured in human primary hepatocytes treated with 
palmitate for 12 hours. 
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Figure 3-20. Mouse primary hepatocytes lack sensitivity to respond to cell death 
and cell migration signals following palmitate exposure. (A) Cell migration assay for 
human KG-1 and murine RAW cells using conditioned media prepared from HepG2, 
human primary hepatocytes (HPH), or mouse primary hepatocytes (MPH) treated with 
either vehicle or palmitate for 12 hours. (B) Direct treatment indicates cell death as 
measured by LDH release of shCTRL HepG2, shCHOP HepG2, or mouse primary 
hepatocytes (MPH) incubated with palmitate for 24 hours. Alternatively, conditioned 
medium was prepared from donor shCTRL HepG2 or MPH cells that were incubated 
with palmitate for 24 hours. The conditioned medium was then applied to recipient of 
shCTRL HepG2, shCHOP HepG2, or mouse primary hepatocytes for 24 hours, as 
indicated, and cell death was measured by LDH release. 
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3.9 Summary 
Excess lipid accumulation is a hallmark of obesity, and lipotoxicity associated 
with saturated FFA has been suggested to result from activation of the UPR observed in 
hepatic steatosis [9]. This study suggests that activation of the UPR plays a pivotal role 
in the pathophysiology of NASH through elevated levels of the UPR and CHOP 
expression (Fig 3-21). Depletion of CHOP in human hepatocytes enhanced survival in 
response to saturated FFA (Fig 3-7 A-B), and CHOP-dependent secretion of key 
cytokines, including IL-8 and TNFα, have central roles in macrophage recruitment and 
hepatocyte lipotoxicity (Fig 3-10 and 3-11). CHOP is suggested to facilitate secretion of 
these factors in hepatocytes exposed to saturated FFA by enhancing phosphorylation of 
p65 at serine 536, triggering NF-κB entry into the nucleus and transcriptional expression 
of a collection of cytokines (Fig 3-12 and 3-21). CHOP induction of NF-κB involves in 
part signaling through IRAK2 protein (Fig 3-15, 3-16, and 3-17). IRAK2 has been linked 
with phosphorylation and activation of NF-κB [150-153], and CHOP is suggested to 
contribute to increased IRAK2 mRNA in hepatocytes exposed to saturated FFAs; 
however, palmitate treatment is suggested to diminish IRAK2 mRNA translation, which, 
as a consequence, leads to no significant change in IRAK2 protein compared with 
nonstressed conditions (Fig 3-15, 3-16, and 3-17).  Depletion of either IRAK2 or RELA 
blocked induction of CXCL8 (IL-8) and TNFA (TNFα) expression in response to 
palmitate, protecting hepatocytes against death and macrophage infiltration (Fig 3-16, 
and 3-21). These results suggest that whereas IRAK2 is required for CHOP activation of 
NF- κB in response to saturated FFA, increased levels of IRAK2 are not sufficient to 
induce NF-κB. Instead, other signals triggered by saturated FFAs contribute in 
conjunction with IRAK2 to induce NF-κB and secreted cytokines. 
 
 79 
 
 
Figure 3-21. Model for UPR regulation during metabolic stress. (G) Model for CHOP 
and UPR regulation of hepatocyte inflammation and death signaling during metabolic 
stress. CHOP regulation of key secreted factors, including TNFα and IL-8, occurs by 
signaling through IRAK2 and NF-κB.  
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CHAPTER 4.  RESULTS: IBTKα facilitates phagophore initiation and protein 
secretion 
4.0 Introduction 
NASH is associated with induction of the UPR and disruption of autophagic flux, 
but the mechanisms by which these processes contribute to the pathogenesis of human 
diseases are unclear. Herein we identify IBTKα as a novel member of the UPR, which 
associates with LC3b, SEC16A, and SEC31A, and plays a previously unrecognized role 
in phagophore initiation and protein secretion from endoplasmic reticulum exit sites. 
Depletion of IBTKα helped prevent accumulation of autophagosome intermediates 
stemming from exposure to saturated free fatty acids and rescued hepatocytes from 
death. Induction of IBTKα and the UPR, along with inhibition of autophagic flux, are 
associated with progression from steatosis to NASH in liver biopsies. These results 
demonstrate a novel function for IBTKα in NASH that links autophagy to the early 
secretory pathway through activation of the UPR. 
 
4.1 IBTKα is a novel UPR member induced by saturated FFAs 
To determine whether IBTKα is preferentially translated in human hepatocytes 
following metabolic stress, we treated human hepatoma HepG2 cells with the saturated 
FFA palmitate or thapsigargin, a pharmacological agent that potently induces ER stress. 
Following 6 hours of treatment, we performed polysome profiling (Figure 4-1 A). Both 
thapsigargin and palmitate resulted in a reduction of heavy polysomes coincident with 
accumulation of monosomes, indicative of lowered global translation initiation compared 
to vehicle treatment. IBTKα mRNA, as well as those encoding preferentially translated 
controls ATF4 and CHOP, were then measured by comparing the percent of each gene 
transcript in each gradient fraction (Figure 4-1 B-C). After either stress treatment, there 
was a significant shift of IBTKα mRNA toward large polysomes compared to vehicle, 
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similar to the expected increase in the ATF4 and CHOP transcripts. Interestingly, IBTKα 
was present in the heaviest polysome fractions 6 and 7 after either thapsigargin or 
palmitate treatment, whereas ATF4 and CHOP were predominantly in polysome 
fractions 4, 5, and 6. This shift of the IBTKα mRNA to the heaviest polysome fractions is 
consistent with the fact that IBTK has a longer coding sequence that can accommodate 
more translating ribosomes compared to ATF4 and CHOP. HepG2 cells deleted for 
PERK (PERK-KO) by using CRISPR/Cas9 retained high levels of translation as viewed 
by heavy polysomes independent of stress (Figure 4-2 A-B) and showed only modest 
changes in fraction distributions of IBTKα, ATF4, or CHOP mRNAs (Figure 4-2 C-D). We 
conclude that PERK is required for repression of global protein synthesis, coincident with 
preferential translation of IBTKα and UPR members in human hepatocytes in response 
to ER stress triggered by lipotoxicity.   
PERK and its downstream effector CHOP also trigger transcriptional expression 
of UPR target genes to alleviate stress or activate inflammation [23, 154]. To determine 
whether IBTKα expression was also regulated at the transcriptional level during 
treatment with palmitate, we generated CHOP knockout (CHOP-KO) HepG2 cells and 
exposed these cells along with WT to saturated FFAs or vehicle (Figure 4-3 A-B). IBTKα 
mRNA and protein were induced only in WT HepG2 cells treated with palmitate, 
whereas basal levels remained unchanged between WT and CHOP-KO cells. These 
results indicate that PERK activation and its downstream effector CHOP are also 
required for induced IBTKα mRNA expression in the UPR. 
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Figure 4-1. IBTKα is preferentially translated following palmitate exposure. (A) 
Polysome profiles of lysates prepared from HepG2 cells treated with palmitate, 
thapsigargin, or vehicle for 6 hours. (B-C) Following polysome analysis, fractions 1 
through 7 were collected and the percentage of ATF4, CHOP, and IBTKα mRNA in each 
were quantified by qPCR and shown as a histogram. The percentage of the total gene 
transcripts in the heavy polysomes (fractions 5-7) for HepG2 treated with either palmitate 
or thapsigargin versus vehicle is indicated for each polysome profile. 
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Figure 4-2. PERK induces preferential translation of IBTKα in response to ER 
stress. (A-B) Polysome profiles of lysates prepared from either HepG2 or PERK-KO 
HepG2 cells treated for 6 hours with palmitate, thapsigargin, or vehicle, as indicated. (C-
D) Following polysome analysis, the percentage of ATF4, CHOP, and IBTKα mRNA 
distributed in fractions 1-7 were quantified by qPCR and are illustrated as histograms.  
The change in the percentage of each gene transcript in the heavy polysomes (fractions 
5-7) for HepG2 treated with either palmitate or thapsigargin versus vehicle is indicated. 
 
  
 84 
 
 
 
Figure 4-3. PERK and CHOP are required for induced IBTKα expression during ER 
stress. (A) WT, PERK-KO, or CHOP-KO HepG2 cells were treated with either vehicle (-) 
or palmitate (+) for 12 hours, followed by immunoblot analysis for the indicated proteins. 
(B) WT, PERK-KO, or CHOP-KO HepG2 cells were treated with either vehicle (-) or 
palmitate (+) for 12 hours, followed by qPCR measurements of IBTKα mRNA. 
 
4.2 Saturated FFAs induce cell death through inhibition of autophagic flux 
While it has been suggested that both apoptosis and autophagy are associated 
with lipotoxicity during NASH [2, 155], it is unclear whether either of these pathways play 
a direct role in hepatocyte death. To determine whether apoptotic pathways are 
involved, we investigated the role of capases in hepatocyte death during lipotoxicity by 
treating HepG2 cells with saturated and unsaturated FFAs, along with staurosporine and 
tunicamycin controls, either alone or in the presence of pan-caspase inhibitor 
ZVAD/FMK (Fig 4-4 A-E). Treatment with saturated FFAs palmitate and stearate 
produced a modest increase in caspase activity, but the addition of ZVAD/FMK did not 
rescue cell death. By contrast, ZVAD/FMK blocked both staurosporine-induced cell 
death and caspase 3/7 activation.  Neither the unsaturated FFA oleate nor the canonical 
UPR activator tunicamycin resulted in appreciable cell death after 24 hours. During 
apoptosis, nuclear localization of cleaved caspase 3 is essential for breakdown of the 
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nuclear lamina and DNA fragmentation [156]. Whereas cleaved caspase 3 was localized 
predominantly to the nucleus after staurosporine treatment as judged by 
immunocytochemistry, total cleaved caspase 3 was reduced and retained in the 
cytoplasm with the addition of ZVAD/FMK (Fig 4-5). By contrast, the low levels of 
caspase 3 activation determined during treatment with saturated FFAs were coincident 
with caspase 3 being retained in the cytoplasm. These results indicate that apoptosis is 
not the predominant mode of hepatocyte death following exposure to saturated FFAs. 
Inhibition of autophagic flux is linked with NASH in human patients [50, 134]. To 
determine if autophagy was associated with activation of the UPR, induction of IBTKα, 
and cell death, we treated HepG2 cells with saturated or unsaturated FFAs for up to 24 
hours and measured key markers of UPR activation as well as LC3b and p62/SQSTM1 
to assess changes in autophagy (Fig 4-6). Increased levels of ATF4 and IBTKα proteins 
were noted by 3 hours after treatment with palmitate and 6 hours of tunicamycin, prior to 
induction of CHOP. Furthermore, palmitate and stearate triggered accumulation of 
lipidated LC3b-II and p62, suggesting that saturated FFAs either induced autophagy or, 
alternatively blocked autophagic flux. Oleate had only a modest effect on the UPR and 
did not alter the autophagic markers, whereas treatment with tunicamycin led to potent 
induction of the UPR and increased LC3b-II but produced only a transient increase in 
p62. 
To determine whether saturated FFAs induce the UPR and interfere with 
autophagic flux, we expressed N-terminal GFP-LC3b in HepG2 cells and assessed its 
co-localization with lysosomes by staining with LAMP2 (Fig 4-7 A). First we treated the 
HepG2 cells with chloroquine, which inhibits proteolysis in the lysosome and hence 
stabilizes LC3b; 75% of GFP-LC3b was colocalized with the lysosomal marker LAMP2, 
indicating that autophagosomes were properly trafficked to the lysosomes. By contrast, 
treatment with palmitate disrupted autophagosome trafficking to the lysosome, with only 
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10% of GFP-LC3b being co-localized with LAMP2 despite a robust induction of 
autophagy. These results clearly indicate that treatment with palmitate leads to a block in 
autophagic flux, which would impair proper trafficking of damaged macromolecules and 
organelles to the lysosome for degradation.   
Does disruption in the autophagic process play an active role in hepatocyte death 
upon exposure to saturated FFAs? We treated HepG2 cells with palmitate alone or in 
combination with agents that disrupt either autophagy initiation (3-methyladenine) or 
lysosomal function (chloroquine or bafilomycin A1) and measured cell death (Fig 4-7 B-
C). To determine if this mechanism was relevant to human hepatocytes, we also 
repeated the experiment with primary human hepatocytes. Addition of 3-methyladenine, 
which prevents induction of autophagy by inhibiting PI3K, increased the survival of both 
HepG2 cells and primary human hepatocytes, whereas the lysosome inhibitors resulted 
in increased death of HepG2 cells. Human primary hepatocytes were more sensitive to 
palmitate induced cell death (>80% compared to 30% in HepG2), therefore adding 
chloroquine and bafilomycin A1 did not increase cell death further.  These results 
suggest that inhibition of autophagic flux, rather than inhibition of phagophore formation 
per se plays an important role in palmitate-induced hepatotoxicity (Fig 4-8). 
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Figure 4-4. Saturated FFAs induce cell death in a caspase-independent manner. 
(A-B) HepG2 cells were treated palmitate, stearate, oleate, tunicamycin, or 
staurosporine in the presence or absence of 20 µM ZVAD/FMK for up to 24 hours and 
cell viability was determined by LDH release and caspase 3/7 activity was measured 
using Apo-ONE biochemical assay. 
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Figure 4-5. Cleaved caspase 3 is not localized to the nucleus by saturated FFAs. 
Sub-cellular localization of cleaved caspase 3 and DNA integrity was visualized using 
immunofluorescence microscopy in HepG2 cells treated with vehicle, palmitate, 
staurosporine, or staurosporine + ZVAD/FMK for 24 hours. 
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Figure 4-6. Saturated FFAs but not unsaturated FFAs induce inhibition of 
autophagic flux. (A-B) HepG2 cells were treated for 24 hours with palmitate, 
tunicamycin, oleate, or stearate and the indicated proteins were measured by 
immunoblot analyses. 
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Figure 4-7. Saturated FFAs cause hepatocyte cell death through an autophagy-
dependent mechanism. (A) HepG2 cells stably transduced with GFP-LC3b were 
treated with vehicle, chloroquine (CQ), or palmitate, and co-localization with LAMP2 was 
visualized using immunofluorescence microscopy and quantified at the pixel level. (B-C) 
HepG2 and primary human hepatocytes (HPH) were treated for 24 hours and viability 
was assessed using LDH release. 
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Figure 4-8. Model for saturated FFA-induced cell death. Model detailing the 
mechanisms for how a block in autophagic flux by palmitate can lead to hepatocyte 
death. 
 
4.3.  IBTKα is required for autophagosome formation and sensitizes hepatocytes 
to lipotoxicity 
To address the hypothesis that IBTKα regulates cell survival by induction of 
autophagy, we generated IBTKα knockdown (shIBTKα) HepG2 cells using shRNA. Both 
shIBTKα and control (shCTRL) cells were assayed for accumulation of LC3b in the 
presence or absence of bafilomycin A1 or chloroquine (Fig 4-9 A). Depletion of IBTKα 
resulted in a loss of conversion of LC3b-I to LC3b-II, as well as a lack of accumulation of 
p62 upon treatment with either bafilomycin A1 and chloroquine. These results suggest 
that IBTKα is not only a downstream UPR target but is also an essential effector in a 
pathway leading to the induction of autophagy prior to LC3b lipidation.   
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Because we previously showed that inhibition of phagophore initiation rescued 
hepatocytes from lipotoxicity (Fig 4-7 B-C), we asked whether depletion of IBTKα would 
also rescue hepatocytes from palmitate induced cell death. To test this idea, we 
depleted HepG2 cells for IBTKα or CHOP using shRNA and measured key stress and 
autophagy protein levels in addition to cell death following palmitate treatment (Fig 4-9 
B-C). As a control, we also characterized HepG2 cells depleted for ATG5, a factor 
known to be required for formation of autophagosomes. Following palmitate exposure, 
each of the three knockdowns resulted in decreased conversion of LC3b-I to LC3b-II, 
coincident with rescue from cell death.  Corresponding mRNA measurements of the 
IBTKα-depleted cells indicated that while IBTKα mRNA was reduced as expected, 
CHOP and its known transcriptional target genes MAP1LC3B and SQSTM1 were not 
affected, suggesting that IBTKα is a unique downstream effector in the UPR (Fig 4-10). 
Of note, mTORC1 remained repressed in all knockdowns following palmitate treatment, 
as measured by phospho-S6K, yet autophagy was not induced. These findings indicate 
that IBTKα is required for the induction of autophagy during activation of the UPR by 
lipotoxicity, and depletion of IBTKα or its upstream regulator CHOP rescue hepatocytes 
from exposure to saturated FFAs. 
We next investigated effects at the ultrastructural level by electron microscopic 
evaluation of WT, CHOP-KO, and IBTKα-KO HepG2 cells treated with bafilomycin A1, 
palmitate, or vehicle (Fig 4-11). Deletion of IBTKα in cells in the absence of stress 
resulted in loss of ER organization and an accumulation of damaged mitochondria (Fig 
4-11 C). Bafilomycin A1 or palmitate treatment of IBTKα-KO cells, but not control cells, 
led to dilation of the ER, suggesting that IBTKα is important for ER organization and 
general trafficking in the adaptive response to ER stress. WT HepG2 cells treated with 
bafilomycin A1 showed accumulation of large autophagolysosomes (Fig 4-11 A); 
however, no autophagosomes were present in either CHOP-KO or IBTKα-KO HepG2 
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cells treated with bafilomycin A1 (Fig 4-11 B-C). Exposure of WT HepG2 cells to 
palmitate also resulted in the appearance of lipid vacuoles throughout the cytoplasm, but 
a lack of autophagolysosomes, consistent with the observation that there was aberrant 
LC3b trafficking to the lysosome (Figure 3H). By comparison, treatment of CHOP-KO 
and IBTKα-KO cells with palmitate resulted in decreased amounts of neutral lipid 
accumulation, still without the appearance of autophagosomes (Fig 4-11 B-C). These 
results support the idea that the UPR plays a direct role in phagophore formation 
through a signaling pathway involving CHOP and IBTKα. 
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Figure 4-9. IBTKα facilitates phagophore induction. (A) shCTRL and shIBTKα 
HepG2 cells were treated with vehicle (V), bafilomycin A1 (BAF), or chloroquine (CQ) for 
up to 24 h and the indicated proteins were measured by immunoblot analyses. (B) 
shCTRL, shIBTKα, shCHOP, and shATG5 HepG2 cells were treated with either vehicle 
(-) or palmitate (+) for 12 hours, and the indicated proteins were measured by 
immunoblots. (C) shCTRL, shIBTKα, shCHOP, and shATG5 HepG2 cells were treated 
with palmitate or vehicle for 24 h and viability was measured by LDH release. 
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Figure 4-10. IBTKα does not prevent expression of MAP1LC3B or SQSTM1. (A-D) 
shCTRL and shIBTKα HepG2 cells were treated with palmitate or vehicle for 12 hours 
and the indicated gene transcripts were measured by qPCR.   
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Figure 4-11. Deletion of CHOP and IBTKα prevents induction of autophagy at the 
ultrastructural level. (A-C) Electron microscopy showing ultrastructural features of WT, 
CHOP-KO, and IBTKα-KO HepG2 cells treated with vehicle, bafilomycin A1, or palmitate 
for 12 hours. 
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4.4 IBTKα induces autophagy by binding to a multisubunit protein complex 
including LC3b at the ERES 
Phagophores have been suggested to form at the ER [157].  Because both 
phagophore induction and ER morphology are dependent upon IBTKα (Fig 4-9 and 4-
11), we wanted to test the hypothesis that IBTKα is central for phagophore formation at 
the ER. We first utilized immunocytochemistry to determine the cellular location of IBTKα 
in WT HepG2 cells treated with chloroquine, palmitate, or vehicle, by staining for 
endogenous IBTKα (Fig 4-12 A). IBTKα was primarily co-localized with the ER marker 
calenxin independent of stress. To assess whether IBTKα is also located at the site of 
autophagosome formation, we used GFP-LC3b HepG2 cells and followed a similar 
experimental design. IBTKα co-localized with only 5% of LC3b in both the vehicle and 
chloroquine treated cells (Fig  4-12 B). However upon treatment with palmitate, which 
would block autophagic flux, IBTKα co-localized with 90% of LC3b. These findings 
indicate that IBTKα co-localizes with phagophores initiating while resident at the ER, but 
not with mature autophagosomes at the lysosome.  
To better understand the mechanism by which IBTKα is involved in phagophore 
initiation at the ER membrane, we treated WT HepG2 cells with palmitate, thapsigargin, 
chloroquine, or vehicle and carried out an immunoprecipitations using antibody specific 
for endogenous IBTKα. Isolated proteins were then digested with trypsin, followed by 
mass spectrometry using multidimensional protein identification technology (MudPIT) 
(Fig 4-12 C-D & Appendix 1). Technical replicate RAW data files were pooled for FASTA 
database searching using SEQUEST, and the resulting dataset was filtered to require a 
false discovery rate of ≤1%. SAINT analysis was performed using the SAINT-express 
algorithm to identify proteins that displayed significant association with IBTK prepared 
from WT cells compared to affinity carried out using IgG control pull-downs. A total of 73 
proteins were identified that met the SAINT probability score of ≥0.8. Of interest among 
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proteins pulled-down with IBTKα with the greatest degree of confidence were SEC16A 
and SEC31A, two essential proteins situated in the ERES, with functions in COPII-
vesicle trafficking and proposed roles in phagophore initiation [100]. The pull-down 
results were consistent with the notion that IBTKα is part of a larger complex that plays a 
role in phagophore formation at the ERES.   
To determine if the IBTKα binding partner SEC16A also plays a direct role in 
phagophore formation and lipotoxicity, we treated HepG2 cells depleted for SEC16A 
expression with either palmitate or vehicle and measured changes in conversion of 
LC3b-I to LC3b-II as well as cell death (Fig 4-13 A-B). Depletion of SEC16A decreased 
initiation of autophagy coincident with enhanced resistance to lipotoxicity. Additionally, 
immunocytochemical analyses of the SEC16A-depleted cells HepG2 cells revealed an 
altered ER morphology and consequent changes in the pattern of IBTKα localization (Fig 
4-13 C). These results indicate that SEC16A is important for ER organization, IBTKα 
localization, and induction of autophagy. 
To further confirm whether IBTKα associates with SEC16A and LC3b, we treated 
WT HepG2 cells with thapsigargin, chloroquine, or palmitate, and then 
immunoprecipated IBTKα, followed by immunoblot analyses of associated proteins (Fig 
4-14 A). We found that independent of stress, IBTKα was complexed with LC3b, along 
with SEC16A, and ULK1/2, which has been suggested to interact directly with LC3b at 
the ERES and be essential for phagophore formation [100, 101, 158]. These same 
protein interactions were observed using reciprocal SEC16A pull-downs, and loss of 
SEC16A expression resulted in disruption of the IBTKα complex (Fig  4-14 B-C). These 
findings suggest that IBTKα associates with a complex including SEC16A, and that this 
complex is essential for recruitment of a key phagophore inducing complex involving 
LC3b and ULK1/2. While IBTKα can be bound to this multisubunit complex independent 
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of stress as judged by pull-down experiments, exposure to saturated FFAs enhance 
expression of IBTKα and the localization of this complex to ERES. 
To further test whether IBTKα associates with SEC31A and to identify additional 
members of the complex, we immunoprecipitated IBTKα from HepG2 cells treated with 
palmitate or vehicle, followed by immunoblot analyses of the bound proteins. IBTKα 
associated with SEC31A, CUL3, along with LC3b independent of treatment with 
saturated FFAs (Fig 4-14 D-F). However, reciprocal pull down of SEC31A indicated that 
LC3b is not part of this complex, suggesting that IBTKα can associate with distinct 
complexes at the ERES that participate in phagophore initiation. 
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Figure 4-12. IBTKα localizes to the endoplasmic reticulum and interacts with a 
variety of biological networks. (A) HepG2 cells were treated with vehicle, chloroquine 
(CQ), or palmitate, and IBTKα and the ER marker calnexin were visualized using 
immunofluorescence microscopy. Co-localization of IBTKα and ER were quantified at 
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the pixel level. (B) HepG2 cells stably expressing GFP-LC3b were treated with vehicle, 
chloroquine (CQ), or palmitate, and co-localization with IBTKα was visualized using 
immunofluorescence microscopy and quantified.  (C) HepG2 cells were treated with 
vehicle, chloroquine (CQ), thapsigargin (Tg) or palmitate (PA).  Cell lysates were used in 
immunoprecipitation experiments with endogenous IBTKα as bait.  The network 
represents proteins, and their functional classes, pulled down following LC/MS analysis 
of eluents. (D) Diagram showing SAINT score against fold change spectral abundance 
for proteins identified in LC/MS analysis of IBTKα immunoprecipitation experiment. 
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Figure 4-13. SEC16A is required for autophagy induction. (A) shCTRL and 
shSEC16A HepG2 cells were treated with either vehicle (-) or palmitate (+) for 12 hours 
and the indicated proteins were measured by immunoblot analyses. (B) shCTRL and 
shSEC16A HepG2 cells were treated for 24 hours and viability was measured by LDH 
release. (C) shCTRL and shSEC16A HepG2 cells were treated with palmitate or vehicle 
for 12h and co-localization of IBTKα and canexin was visualized using  
immunofluorescence microscopy.    
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Figure 4-14. IBTKα associates with protein complex at the ERES and induces 
formation of phagophores. (A-B) HepG2 cells were treated for 12 hours with the 
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indicated stress compound and cell lysates were used for immunoprecipitation with IgG 
control (mock), IBTKα, or SEC16A followed by immunoblot analysis.  On the left of panel 
H, input indicates the immunoblot analyses of total lysates. (C) shCTRL and shSEC16A 
HepG2 cells were treated for 12 hours with vehicle or palmitate and cell lysates were 
used for immunoprecipitation with IgG control (mock) or IBTKα followed by immunoblot  
analysis. On the left of panel J, input indicates the immunoblot analyses of total lysates. 
(D-E) HepG2 cells were treated with palmitate or vehicle for 12 hours and cell lysates 
were used for immunoprecipitation with IgG control (mock), IBTKα, or SEC16A followed 
by immunoblot analysis to measure the indicated proteins. On the left of panel A, input 
indicates immunoblot analyses carried out using total lysates. (F) shCTRL and 
shSEC31A HepG2 cells were treated with vehicle or palmitate for 12 hours, and cell 
lysates were used for immunoprecipitation with IgG control (mock) or IBTKα, followed by 
immunoblot analyses to measure the indicated proteins. 
 
4.5 IBTKα and the UPR activate NF-κB and secretion of cytokines triggering 
lipotoxicity 
We previously determined that treatment of hepatocytes with saturated FFAs 
induces a PERK/CHOP pathway in the UPR, leading to activation of NF-κB by a process 
involving phosphorylation of the subunit p65/RelA at serine 536 and consequent induced 
secretion of many cytokines [47]. Lowered NF-κB activity subsequently blocked induced 
expression and secretion of TNFα and IL-8 [47]. Deletion of CHOP in HepG2 cells, 
which would thwart initiation of autophagy and therefore alleviate accumulation of 
suggested toxic autophagosome intermediates during exposure to saturated FFAs, 
prevented p65 phosphorylation at serine-536 (Fig 4-9 B). Because phosphorylation of 
p65 is linked with induction of NF-κB transcriptional activity [87], we wanted to determine 
if depletion of IBTKα, or its interacting partner SEC31A, also prevented induction of NF-
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κB-directed expression of TNFα, and IL-8 in response to palmitate treatment. SEC31A is 
not only critical for formation of COPII vesicles at the ERES [159], but is also suggested 
to be positioned in phagophores during assembly [100]. Depletion of either IBTKα or 
SEC31A in the HepG2 cells significantly lowered phosphorylation of p65 at serine 536 
and LC3b-II conversion in response to palmitate exposure, as well as reduced 
lipotoxicity (Fig 4-15 A- B). Additionally, depletion of SEC16A or ATG5 prevented 
phosphorylation of p65, suggesting that NF-κB activation during lipotoxicity is dependent 
upon the induction of autophagy (Fig 4-15 C). Levels of secreted IL-8 and TNFα were 
measured by sandwich ELISA and both cytokines were lowered by >100-fold in the 
vehicle and palmitate treated shCHOP, shIBTKα, and shSEC31A cells (Fig 4-16 A-B). 
Additionally, CHOP and IBTKα were required for expression of CXCL8 (IL-8) and TNFA 
(TNFα) mRNAs (Fig 4-16 C-D). These findings indicate that lowered secretion of TNFα 
and IL-8 in the IBTKα-depleted cells was not merely a consequence of loss of COPII-
directed secretion, which may occur with disruption of the protein complexes featuring 
SEC16A and SEC31A at the ERES [159].   
To address whether general secretion also involves the IBTKα and associated 
proteins at the ERES that facilitate initiation of autophagy, we transfected control and 
HepG2 cells depleted for IBTKα, CHOP, SEC16A, or SEC31A with a Gaussia luciferase 
reporter construct and measured secreted luciferase activity in the cell culture media 
following treatment with either vehicle of palmitate (Fig 4-17 A). Depletion of each of the 
four gene targets resulted in a reduction of Gaussia luciferase secretion. These findings 
suggest that the assembled multisubunit protein complexes containing IBTKα at the 
ERES are integral to secretion emanating from the ER, as well as the formation of 
autophagosomes. 
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We previously showed that secreted TNFα is central for hepatocellular death 
upon exposure to saturated FFAs [47]. We addressed this idea by adding recombinant 
TNFα to WT, shCHOP, and shIBTKα HepG2 cells in the presence or absence of 
palmitate treatment. There was significant death of shCHOP and shIBTKα cells only 
after treatment with TNFα in combination with palmitate (Fig 4-17 B), which was 
accompanied by increased phosphorylation of p65 (Fig 4-17 C). These results indicate 
that IBTKα is essential for cytokine expression and secretion and consequent inhibition 
of autophagic flux during metabolic stress. 
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Figure 4-15. IBTKα is required for NF-κB activation during exposure to saturated 
FFAs. (A) shCTRL, shCHOP, shIBTKα, and shSEC31A HepG2 cells were treated with 
vehicle (-) or palmitate (+) for 12 hours and cell lysates were used for immunoblot 
analyses to determine the levels of the indicated proteins. (B) shCTRL and shSEC31A 
HepG2 cells were treated with palmitate for 24 hours and cell viability was measured by 
LDH release. (C) shCTRL, shSEC16A, and shATG5 HepG2 cells were treated with 
either vehicle (-) or palmitate (+) for 12 hours and cell lysates were used for immunoblot 
analyses to determine the levels of the indicated proteins. 
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Figure 4-16. IBTKα and the UPR are required for secretion of cytokines. (A-B) 
shCTRL, shCHOP, shIBTKα, and shSEC31A HepG2 cells were treated with vehicle or 
palmitate for 12h and IL-8 and TNFα release was measured by sandwich ELISA. (C-D) 
shCTRL, shCHOP, and shIBTKα HepG2 cells were treated with vehicle or palmitate for 
12 hours and the levels of CXCL8 (IL-8) and TNFA (TNFα) mRNAs were measure by 
qPCR. 
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Figure 4-17. IBTKα and the UPR activate NF-κB triggering lipotoxicity. (A) shCTRL, 
shCHOP, shIBTKα, shSEC16A, and shSEC31A HepG2 cells were transfected with a 
Gaussia luciferase reporter and treated with vehicle or palmitate for 12 hours.  
Luciferase activity was measured in the supernatant. (B) Cultured shCTRL, shCHOP, 
and shIBTKα HepG2 cells were treated for 24 hours with recombinant TNFα, and 
palmitate, alone or in combination, as indicated, and cell viability was measured by LDH 
release. (C) shCTRL, shCHOP, and shIBTKα HepG2 cells were treated for 24 hours with 
recombinant TNFα and/or and palmitate, as indicated, and the indicated proteins were 
measured by immunoblot analyses. 
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4.6 The UPR and NF-κB are induced in human liver biopsies of NASH patients 
To determine if the mechanism proposed from the HepG2 and primary human 
hepatocyte studies are truly relevant to disease progression in human liver, we 
investigated induction of the UPR and autophagy in a set of liver biopsy samples from 
patients matched for BMI and age following bariatric surgery (Table 4-1). Patients were 
categorized after histological evaluation and standard scoring for NASH, comprising of 
steatosis grade, degree of fibrosis, and presence of hepatocellular ballooning and 
lobular inflammation. Levels of CHOP, p65, phosphorylated p65, and IBTKα were 
increased in the livers of patients with simple steatosis and NASH relative to normal 
control (Fig 4-18 A-E). Additionally, inhibition of autophagic flux was observed in NASH 
patients as measured by LC3b-II conversion and p62 (Fig 4-18 F-G), consistent with 
severe hepatocellular injury markers such as ballooning (Fig 4-18 H-I). These findings 
indicate that the UPR, including CHOP and IBTKα, and NF-κB are activated in patients 
with NAFLD, and as the disease progresses from simple steatosis to NASH, there is a 
strong correlation with inhibition of autophagic flux. 
To address whether UPR and NF-κB activation are associated with increased 
cytokine secretion, we performed a cytokine panel on serum from patients (Fig 4-19 A-C 
and Table 4-2). Levels of IL-6, IL-8, and TNFα were elevated in NASH patients, whereas 
only IL-6 and TNFα were elevated in those with simple steatosis. These results, along 
with all other metadata collected on the human samples, were utilized to carry out a 
principle component analysis (Fig 4-20 A-B). From this analysis, we identified a mixture 
of cell based and serum biomarkers that are closely related to NASH, steatosis, or both 
NAFLD states. For example, CHOP, IL-8, AST, LC3b, and p62 correlate strongly with 
NASH, whereas IBTKα, phosphorylated p65, and TNFα correlate with both NAFLD 
states. 
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Table 4-1. Clinical features and histological evaluation and scoring for NASH from 
patients that provide liver biopsy samples. Summary of histological and clinical 
chemical parameters from liver biopsies and matched sera of patients. 
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Figure 4-18. The UPR and NF-κB are upregulated in simple steatosis and NASH. 
(A) Representative immunoblot measurements for the indicated proteins in lysates 
prepared human liver biopsy samples of patients with normal liver, simple steatosis, or 
NASH. (B-G) Protein quantification of immunoblots from lysates of human liver biopsy 
samples (n=10 per group).  Data is shown as mean +/- standard error of the mean 
(SEM).  (H-I) Protein quantification of immunoblots for LC3b-II and SQSMT1 from 
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lysates prepared from human liver biopsy samples of patients grouped by histological 
presence of ballooning. Data is shown as mean +/- SEM.   
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Figure 4-19. IL-8, TNFα, and IL-6 are present in serum of NASH patients. (A-C) 
Circulating levels of IL-8, TNFα, and IL-6 from serum of patients to matched liver biopsy 
samples.  
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Table 4-2. Cytokine panel on serum from patients providing liver biopsy samples. 
Cytokine, chemokine, and DAMP measurements of biomarkers from serum of patients to 
matched liver biopsy samples. 
  
 116 
 
 
Figure 4-20. Principal component analysis correlates biomarkers with simple 
steatosis and NASH. (A) Principal component analysis combining all cytokine data, 
histological and clinical chemistry findings, as well as protein quantification from liver 
biopsy samples. (B) Abridged correlation table from principal component analysis.    
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4.7 Summary 
Accumulation of saturated FFAs and activation of the UPR activation are 
common features associated with NAFLD; however, how the UPR contributes to the 
progression from simple steatosis to NASH is not clear [9]. Our study indicates that 
activation of the UPR and IBTKα, in combination with inhibition of autophagic flux during 
exposure to saturated FFAs, is as a key driver of hepatocellular death and the 
pathophysiology of NASH (Fig 4-21 a). IBTKα expression was induced as part of the 
UPR by both translational and transcriptional control mechanisms (Fig 4-1, 4-2, and 4-3), 
and loss of IBTKα in human hepatocytes thwarted induction of autophagy and enhanced 
survival of hepatocytes exposed to saturated FFAs (Fig 4-9). Translational control during 
ER stress allows for rapid enhanced expression of IBTKα and consequent assembly of a 
multisubunit complex at the ERES that included key factors, such as LC3b, ULK1/2, 
SEC16A, and SEC31A that served to promote phagophore initiation (Fig 4-14).  In 
response to saturated FFAs, the UPR and CHOP trigger a signaling pathway involving 
NF-κB, which induces transcriptional expression of key cytokines that contribute to 
inflammation and cell death (Fig 4-15, 4-16, and 4-21 B). Among these cytokines, TNFα 
is suggested to function as an autocrine and paracrine factor that contributes to cell 
death and amplifies NF-κB-directed gene expression (Fig 4-21 B). Enhanced levels of 
IBTKα can also promote formation of vesicles from the ER that facilitate secretion of 
these cytokines (Fig 4-16). IBTKα may function as a multidomain adaptor protein in the 
assembly of the protein complex at the ERES and/or help direct E3 ubiquitin ligase 
CUL3 ubiquitylation of proteins required for assembly or function of the complex. 
Importantly, loss of SEC31A did not disrupt IBTKα association with SEC16A or LC3b, 
suggesting that there are distinct complexes including IBTKα that are situated at the 
ERES (Fig 4-21). The coupled effect of autophagy initiation and secretion through 
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interaction with key proteins at the ER places IBTKα at a pivotal intersect between cell 
survival pathways, which given metabolic stress can result in adverse consequences. 
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Figure 4-21. Model for Role of IBTKα in the Pathogenesis of NASH. (A) Model for 
the UPR and IBTKα regulation of autophagy induction at the ERES during metabolic 
stress. Saturated FFAs induce the UPR, featuring induced transcriptional expression of 
IBTKα by CHOP and preferential translation by eIF2α-P. IBTKα assembles in a multi-
subunit complex with SEC16A, ULK1/2, and LC3b at the ERES, culminating in induction 
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of phagophores. Saturated FFAs also block the autophagic flux, contributing to 
hepatocyte death. (B) Model for the UPR and IBTKα regulation of secretion through 
COPII vesicles during metabolic stress. Induced secretion of key cytokines, including 
TNFα and IL-8, play a key role in hepatocyte cell death and inflammation during 
lipotoxicity. 
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CHAPTER 5.  RESULTS: CHOP and NF-κB coordinately regulate proteasome 
activity through NRF2 following a block in autophagic flux 
 
5.0 Introduction 
 NASH is associated with activation of CHOP and NF-κB, but the biological 
networks that these transcription factors regulate during the progression of 
hepatocellular injury have not been fully elucidated. In this study, we carried out ChIP-
seq and RNA-seq analyses on hepatocytes deleted for either CHOP or the p65 (RELA) 
subunit of NF-κB and determined how these transcription factors coordinately regulate 
global gene expression patterns following exposure to palmitate. Additionally, we found 
that inhibition of autophagic flux, a key driver of hepatocellular death during the 
progression of NASH, results in activation of the proteasome. Induction of proteasomes 
occurs via a signaling pathway featuring the transcription factor NRF2, which is 
suggested to serve as an adaptive response to hepatocyte injury. These results provide 
mechanistic insight into global transcriptional networks co-regulating autophagy and 
proteasome pathways and their roles in both hepatocellular injury and adaptive 
responses during the pathogenesis of NASH. 
 
 
5.1 CHOP and NF-κB mediate palmitate-induced hepatocellular injury  
 In Chapter 4, we showed that CHOP regulates hepatocellular injury through 
inhibition of phagophore formation and secretion of cytokines, such as TNFα. We also 
addressed the underlying CHOP signaling networks and showed that CHOP is required 
for the secretion of cytokines such as TNFα through activation of the p65 subunit of NF-
κB (Fig 3-21), and that CHOP mediates both phagophore induction and COPII vesicle 
mediated secretion through IBTKα (Fig 4-21). To address whether CHOP and NF-κB 
activation are required for IBTKα protein expression, we treated WT HepG2 cells 
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depleted for either CHOP (CHOP-KO) or p65 (RELA-KO) with vehicle or palmitate. In 
WT cells there was a sharp increase in IBTKα mRNA after palmitate treatment, which 
was largely absent with loss of CHOP or NF-κB functions (Fig 5-1 A). To be certain that 
the induction of IBTKα mRNA was a consequence of transcriptional regulation, a 
reporter was constructed that fused the IBTKα promoter to GFP, and this reporter was 
introduced into the HepG2 cells.  Whereas GFP expression was increased in WT cells 
following palmitate exposure, there was minimal change in the CHOP-KO and RELA-KO 
cells (Fig 5-1 B). Finally we determined that IBTKα protein expression was only induced 
in WT cells exposed to palmitate but not in RELA-KO or CHOP-KO cells (Fig 5-1 C). We 
conclude that expression of IBTKα is induced in hepatocytes following treatment with 
saturated FFAs by a mechanism requiring CHOP and NF-κB-directed transcription of 
IBTKα. Coincident with decreased IBTKα protein expression, LC3b-II lipidation and p62 
accumulation were reduced in both the CHOP-KO and RELA-KO cells treated with 
palmitate (Fig 5-1 C). To determine if lowered induction of autophagy resulted in 
increased cell viability, we measured cell death by LDH release (Fig 5-1 D). After 
palmitate exposure, both CHOP-KO and RELA-KO cells resulted in reduced cell death 
compared with WT. These results, combined with those in Chapter 4, indicate that both 
CHOP and NF-κB are required for autophagic cell death through a mechanism involving 
induced IBTKα expression. 
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Figure 5-1. CHOP and NF-κB are required for palmitate-induced lipotoxicity. (A) 
WT, CHOP-KO, and RELA-KO HepG2 cells were treated with either vehicle or palmitate 
for 12 hours, followed by qPCR measurements for IBTKα mRNA. (B) Wild type, CHOP-
KO, and RELA-KO HepG2 cells were transfected with a construct containing the 
promoter of the IBTKα gene that was fused with the GFP coding sequence, followed by 
treatment with either vehicle or palmitate for 12 hours. Results are shown as the fold 
change in GFP signal intensity relative to WT treated with only vehicle. (C) WT, CHOP-
KO, and RELA-KO HepG2 cells were treated with either vehicle (-) or palmitate (+) for 12 
hours, followed by immunoblot analysis for the indicated proteins. (D) WT, CHOP-KO, 
and RELA-KO HepG2 cells were treated with palmitate for 24 hours and cell death was 
measured by LDH release.  
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5.2 CHOP and NF-κB share target genes 
 In Chapter 3, we showed that CHOP is required for the phosphorylation of p65 at 
serine 536 and consequent nuclear localization following palmitate exposure, resulting in 
increased expression of pro-inflammatory cytokines and chemokines, such as TNFα and 
IL-8 [47]. In addition to IBTKα gene expression, CHOP has been reported to contribute 
to induction of autophagy genes such as BECLN1, MAP1LC3B, SQSTM1, and several 
ATG family members [56, 160]; however, it is not known whether CHOP or NF-κB are 
direct regulators of these genes and others induced by saturated FFAs. To identify 
genes directly regulated by CHOP and phosphorylated p65 (P~p65), we carried out 
genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) on WT HepG2 
cells treated with either vehicle or palmitate for 12 hours (Fig 5-2 and Appendix 2). We 
identified 1499 unique peaks for CHOP and 542 unique peaks for P~p65 binding to 
DNA, which were assigned to the nearest transcription start sites (TSSs) of known 
human genes using USCS gene annotation (hg19). 8.8% of the CHOP and 2.1% of the 
P~p65 binding sites were <3 kilobases (kb) from the TSSs, whereas 35% of the CHOP- 
and 50.4% of the P~p65 binding sites were >3kb from the TSSs (Fig 5-2 A). 
Interestingly, a total of 61 genes <3kb from the TSS and 1728 genes >3kb from the TSS 
were bound by both CHOP and P~p65 (Fig 5-2 B and Appendix 2). This finding 
suggests that a small, but significant, portion of the CHOP and NF-κB –targeted genes 
are bound by both transcription factors.   
A DNA binding motif for CHOP was found to be similar to that of p50, the 
canonical binding partner to p65 in NF-κB (Fig 5-2 C). Additionally, the p65 subunit of 
NF-κB has been shown to associate with several isoforms of C/EPB, a family of bZIP 
transcription factors to which CHOP also belongs [161]. To address whether CHOP and 
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P~p65 proteins can associate with each other, we carried out CHOP pull-down using 
CHOP-specific antibodies, and then carried out an immunoblot analyses of proteins in 
the immunopreciptation. P~p65 was present in the CHOP pull-down, along with ATF4, 
which was previously reported to complex with CHOP in HepG2 cells (Fig 5-2 D).  These 
findings suggest that CHOP can indeed associate with P~p65 in human hepatocytes.  
 126 
 
 
 
Figure 5-2. CHOP and NF-κB bind to the promoters of a collection of genes. (A) 
Distribution of CHOP and P~p65 ChIP-seq peaks across the human genome. The 
percentages indicate the representative peaks called for each segment of the genome: 
Introns, <3kb from the TSS, >3kb from the TSS, Exons, 5’-untranslated region, and 3’-
untranslated region. (B) Total number of peaks called for CHOP, P~p65, or both CHOP 
and P~p65 binding for either <3 kb and >3 kb from the TSS. (C) Binding motifs identified 
from CHOP and P~p65 ChIP-seq peaks as well as known proteins which bind the same 
motif. (D) Immunoprecipitation of CHOP in wild type HepG2 cells treated with either 
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vehicle (-) or palmitate (+) for 12 hours, followed by immunoblot analysis of the indicated 
proteins. 
5.3 RNA-seq reveals CHOP and NF-κB coordinately regulate global gene 
expression 
 Do CHOP and NF-κB coordinate changes in mRNA expression during the 
pathogenesis of NASH? The genes expression networks regulated by CHOP and NF-κB 
have been well studied in in vitro murine models, but it is not known how these 
transcription factors regulate gene expression in hepatocytes with regards to the 
pathogenesis of simple steatosis to NASH. Hence, we chose to carry out RNA-seq 
analyses on WT, CHOP-KO, and RELA-KO HepG2 cells treated with either vehicle or 
palmitate for 12 hours to understand the gene regulatory networks control by CHOP and 
NF-κB. Following palmitate treatment, we found that the mRNA levels for 2327 genes 
were significantly induced and 1237 genes were significantly repressed using a false 
discovery rate of 0.05 as a cutoff. We compared these genes to the ChIP-seq binding 
peaks to address whether any of these genes were directly regulated by CHOP or 
P~p65 (Fig 5-3 A-B). We found that 244 out of the 2327 (10%) genes induced following 
palmitate exposure also showed direct binding by CHOP and P~p65 individually, or both 
Fig 5-3 A), whereas 141 of the 1237 (11%) genes repressed following palmitate 
exposure had direct binding by CHOP, P~p65, or both (Fig 5-3 B). These findings 
suggest that among all genes showing significant changes upon loss of either CHOP 
and NF-κB, these transcription factors bind directly to a subset, and that other gene 
regulation might be either indirect or through the regulation of additional control 
mechanisms.    
In order to understand how CHOP and NF-κB are regulating gene expression at 
a more global level, we compared statistically significant genes from the RNA-seq data 
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set across wild type, CHOP-KO, and RELA-KO HepG2 cells (Fig 5-4 A). We found that 
both CHOP and P-p65 coordinately regulate gene expression at a global level. To 
further understand the biological pathways that the transcription factors were regulating, 
we performed a gene ontology analysis using DAVID, and found that depletion of either 
CHOP and P~p65 suggest their involvement in the upregulation of biological pathways 
such as DNA replication, electron transport chain, and cell cycle, as well as 
downregulation of biological pathways such as inflammation, cell death, and proteasome 
degradation (Fig 5-4 B). Collectively, this indicates that CHOP and NF-κB coordinately 
regulate both global gene expression as well as distinct biological networks involved in 
cellular injury following treatment with palmitate, but only a small percentage (10-11%) is 
through direct promoter binding.   
Of the genes suggested to be directly regulated by CHOP and/or NF-κB, 
functional annotation clustering was performed using the DAVID Bioinformatics 
Database to identify GO ontology terms associated with both up- and down-regulated 
gene sets following palmitate treatment (Fig 5-5 A and B). A large portion of the 
upregulated genes directly bound by CHOP and NF-κB were involved in cell cycle 
control and transcriptional regulation, with the later providing a rationale for the 
expression of the large number of regulated genes that were not directly bound by either  
CHOP or NF-κB. CHOP and NF-κB also induced genes involved in proteolysis.  
Additionally, genes involved in regulation of cell size, lipid metabolism, and kinase 
activity were repressed. Additionally, we found that CHOP and P~p65 bound to 
promoters of pro-inflammatory genes that are upregulated following palmitate exposure 
(5-5 A and 5-6 A-B).  
 In addition to increased inflammation, we also observed GO ontology terms 
associated with decreased lysosome function, including TFEB and SORT1, which are 
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important for genes involved in lysosomal function and trafficking, respectively (Fig 5-5 
A-B). This may help explain some of our findings from Chapter 4, where we showed that 
palmitate results in a block in autophagic flux which prevents the trafficking of 
autophagosomes to lysosomes resulting in increased cell death (Fig 4-7 and 5-1). 
Additionally, to determine whether CHOP and NF-κB directly regulates genes involved in 
the induction of autophagy after treatment with palmitate in addition to IBTKα, we 
identified known genes essential for the induction of autophagosomes from the ChIP-seq 
dataset and compared the RNA-seq expression profile in WT, CHOP-KO, and RELA-KO 
for the corresponding genes (Fig 5-6 C-D). We found that CHOP and P~p65 bound to 
the promoters of many genes that were essential for the induction and maintenance of 
autophagy, including SEC16A, which we previously found to associate in a protein 
complex with IBTKα to induce phagophores (Fig 4-12 and 4-14). Many of the proteins 
identified as regulated directly by CHOP and P~p65 are involved in the early stages of 
phagophore initiation and trafficking, including ATG12, ARF6, and RAB32. While both 
CHOP and P~p65 associated to the promoter of IBTKα, the preferential binding to gene 
promoters coincident with repressed gene expression in the CRISPR-KO cells indicates 
that CHOP and P~p65 directly regulate a set of genes to control the activation of 
autophagy, and that defective trafficking of autophagosomes to the lysosome is a key 
feature of hepatocellular injury during NASH (Fig 4-7 and 5-6 C-D).  
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Figure 5-3. CHOP and NF-κB regulate unique genes sets. (A) Transcription factor 
binding sites from CHOP and P~p65 ChIP-seq are illustrated in the red and yellow in the 
Venn diagram.  These binding sites are overlayed with induced genes (orange) following 
palmitate exposure as identified by RNA-seq. (B)  Transcription factor binding sites from 
CHOP and P~p65 ChIP-seq were overlayed with the repressed genes following 
palmitate exposure as identified by the RNA-seq analysis. 
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Figure 5-4. CHOP and NF-κB co-regulate multiple biological pathways. (A) Global 
gene expression profile from RNA-seq data set of wile type, CHOP-KO, and RELA-KO 
HepG2 cells treated with either vehicle or palmitate for 12 hours. Genes are clustered 
using Euclidean clustering. (B) Heat maps from RNA-seq analysis depicting biological 
pathways co-regulated by CHOP and NF-κB. Red depicts induced genes and blue 
depicts repressed genes. Pathways were identified using DAVID gene ontology. Genes 
are clustered using Euclidean clustering. 
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Figure 5-5. CHOP and NF-κB regulate unique genes to control overlapping 
biological pathways. DAVID analysis followed by a functional annotation clustering of 
the top induced genes (A) and repressed genes (B) following palmitate treatment was 
performed. Associated go ontology terms along with the enrichment scores are located 
on the left, and the corresponding transcription factor which binds to the promoter is 
indicated by a “+” on the right.  
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Figure 5-6. CHOP and NF-κB regulate unique genes to control inflammation and 
autophagy. (A) Genes involved in inflammation directly bound by either CHOP, P~p65, 
or both CHOP and P~p65 as identified through ChIP-seq analysis. RNA-seq data is 
shown as fold change from wild type untreated. (B) Venn diagram depicting genes 
directly bound by CHOP and/or P~p65 involved in inflammation. (C) Genes involved in 
the induction of autophagy directly bound by either CHOP, P~p65, or both CHOP and 
P~p65 as identified through ChIP-seq analysis. RNA-seq data is shown as fold change 
from wild type untreated. (D) Venn diagram depicting genes directly bound by CHOP 
and/or P~p65 involved in the induction of autophagy.  
  
 134 
 
5.4 CHOP and NF-κB activate the proteasome through NRF2 
 Global gene expression analysis by RNA-seq revealed that although CHOP and 
NF-κB were involved in reduced lysosome function, they coordinately contribute to the 
activation of genes involved in proteasome activity (Fig 5-4 and 5-6), suggesting that 
there is a compensatory process to insure a certain level of proteolysis capacity in cells. 
To test this idea biochemically, we treated WT, CHOP-KO, and RELA-KO HepG2 cells 
with either vehicle or palmitate for 24 hours and measured proteasome activity using the 
chymotrypsin-like proteasome-glo assay (Fig 5-7 A). Whereas palmitate resulted in a 10-
fold increase in proteasome activity in WT cells, lowered activity was observed in both 
vehicle and palmitate-treated CHOP-KO and RELA-KO cells.  
NRF2 (NFE2L2) has been shown to transcriptionally regulate proteasome 
subunits such as the chymotrypsin-like β5 ring PSMB5 in response to DNA damaging 
agents such as 3-methylcholanthrene and antioxidants such as sulforaphane [162-164]. 
We identified the NRF2 transcription factor to be directly regulated by both CHOP and 
P~p65 in our ChIP-seq and RNA-seq data sets (Appendix 2). To further validate these 
findings, we transfected WT, CHOP-KO, and RELA-KO HepG2 cells with a construct 
containing the promoter region of NFE2L2 fused to the GFP reporter, followed by 
treatment with either vehicle or palmitate for 12 hours. Expression of the GFP reporter 
was increased over 4-fold in WT cells after treatment with palmitate, with minimal 
induction in the CHOP-KO and RELA-KO cells (Fig  5-7 B). Additionally, we observed 
increased NRF2 mRNA and protein in palmitate-treated WT cells, as measured by 
qPCR and immunoblot analyses, respectively (Fig 5-7 C-D).  There was minimal 
expression of either NRF2 mRNA or protein in either CHOP-KO or RELA-KO cells. 
Furthermore, NRF2 localized to the nucleus upon palmitate treatment (Fig 5-7 E). 
 135 
 
Collectively, these results indicate that CHOP and NF-κB are required for transcriptional 
induction of NFE2L2 (NRF2) mRNA and protein levels in response to palmitate. 
 Following nuclear localization, NRF2 binds to the promoter of genes encoding 
subunits of proteasomes, including PSMB5 that is critical for chymotrypsin-like activity, 
as well as antioxidant genes NQO1, GCLC, and GSR [165, 166]. Both CHOP and NF-κB 
were required for induction of these NRF2 target genes in response to palmitate (Fig 5-8 
A-D). Additionally, we identified several proteasome subunits in the ChIP-seq analysis 
that were suggested to be directly regulated by CHOP and/or P~p65, and each of these 
were confirmed by qPCR (Fig 5-8 E-H). These results suggest that CHOP and P~p65 
coordinately regulate proteasome expression following palmitate treatment through both 
NRF2, as well as suggested direct regulation of genes encoding selected proteasome 
subunits (Fig 5-8 I). 
 136 
 
 
 
Figure 5-7. CHOP and NF-κB regulate proteasome activation through NRF2. (A) WT 
HepG2, CHOP-KO, and RELA-KO cells were treated with palmitate or vehicle for 24 
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hours and proteasome activity was measured by the chymotrypsin proteasome-glo 
assay. (B) WT, CHOP-KO and RELA-KO cells were transiently transfected with a 
reporter containing the NFE2L2 promoter fused to the GFP reporter, followed by 
treatment with vehicle or palmitate for 12 hours. (C) WT, CHOP-KO, and RELA-KO cells 
were treated with palmitate or vehicle for 12 hours and NFE2L2 mRNA levels were 
measured by qPCR. (D) WT, CHOP-KO, or RELA-KO cells were treated with vehicle (-) 
or palmitate or oleate (+) for 12 hours and immunoblot analyses were carried out to 
measure the indicated proteins. (E) Nuclear localization of NRF2 protein was measured 
by Immunofluorescence microscopy in HepG2 cells that were treated with palmitate or 
vehicle. In parallel, Hoeschst staining was used to visualize nuclei, and the nuclear 
staining and NRF2 imaging was merged.   
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Figure 5-8. Palmitate exposure induces NRF2 targets and proteasome subunits. 
(A-H) WT, CHOP-KO, and RELA-KO cells were treated with palmitate or vehicle for 12 
hours and and the indicated mRNAs were measured by aPCR. (I) Venn diagram 
indicating CHOP and P~p65 regulation of genes involved in proteasome function. Genes 
were identified by ChIP-seq as being bound by CHOP and P~p65, individually or in 
combination.  
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5.5 Inhibition of autophagic flux enhances NRF2 transcriptional activity 
Does NRF2-mediated proteasome activation require autophagy? Recent 
literature has suggested a high degree of crosstalk between autophagy and the 
ubiquitin/proteasome system [167]. Because both CHOP and NF-κB are required for the 
initiation of autophagy as well as NRF2 expression (Fig 5-1, 5-6 and 5-7), we address 
whether the induction of autophagy itself was also required for proteasome activation. To 
explore this concept, we treated cells depleted for IBTKα or ATG5, a well-established 
factor required for formation of phagophores, with palmitate and did not observe an 
increase in chymotrypsin-like and caspase-like proteasome activity coincident with 
decreased initiation of autophagy (Fig 5-9 A-B). These results suggest that induction of 
autophagy is important for enhanced proteasome activation following palmitate 
exposure.  We suggest that cell changes occurring with accumulating autophagosomes 
that are blocked in flux are critical for the NRF2 induction.  
Inhibition of autophagic flux results in an accumulation of macromolecules and 
proteins, including an up-regulation of LC3b-II and p62, crucial regulatory proteins 
involved in trafficking autophagic cargo to the lysosome for degradation [98, 99]. Recent 
reports suggested that p62 aggregates can directly inhibit the KEAP1-NRF2 complex, 
resulting in activation of NRF2 [168]. To explore the idea that inhibition of autophagic flux 
and consequent accumulation of p62 can lead to NRF2 activation, we treated a variety 
of autophagy inducers and blockers of autophagic flux and measured NRF2 protein 
levels (Fig 5-10 A). Compounds which inhibited autophagic flux, including palmitate, 
choroquine, bafilomycin A1, and thapsigargin, resulted in both an accumulation of p62 
and NRF2, as well as enhanced proteasome activity (Fig 5-10 A-B). Because NRF1 has 
also been reported to enhance proteasome activity through elevating expression levels 
of proteasome subunits [20], we evaluated NRF1 protein levels but observed no change 
with response to compound treatment (Fig 5-10 A). These results suggest that with 
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inhibition of autophagic flux there is increased NRF2 protein levels that can trigger 
enhanced proteasome activity. 
During inhibition of autophagic flux there are accumulating amounts of p62, and it 
was suggested that increased levels of p62 can bind to KEAP1 and disrupt the KEAP1-
NRF2 complex, preventing NRF2 proteasome degradation and allowing for NRF2 
nuclear localization [168]. To determine whether p62 forms a complex with KEAP1 
following inhibition of autophagic flux in human hepatocytes, we treated WT HepG2 cells 
with vehicle, palmitate, choroquine, or thapsigargin and carried out an 
immunoprecipitation using an antibody specific for KEAP1 and IgG as a control, followed 
by immunoblot analysis for KEAP1 and associated p62 protein (Fig 5-11 A). There were 
increased levels of p62 complexed with KEAP1 when cells were treated with palmitate, 
chloroquine, and thapsigargin, all inhibitors of autophagic flux. Next, to understand if the 
increased levels of p62 and consequent nuclear localization of NRF2 directly affected 
proteasome activation, we transfected HepG2 cells with a plasmid expressing p62 (Fig 
5-11 B-C). Overexpression of p62 resulted in increased NRF2 levels, as well as 
enhanced proteasome activity. Collectively, these results indicate that inhibition of 
autophagic flux leads to an association of p62 with KEAP1, and increased p62 levels 
result in enhanced proteasome activity consequent with induced NRF2 protein 
expression. 
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Figure 5-9. Autophagy is required for NR2-mediated proteasome activation. (A) 
shCTRL, shATG5, and shIBTKα HepG2 cells were treated with vehicle (-) or palmitate 
(+) for 12 hours and immunoblot analyses were carried out indicated proteins. (B) 
shCTRL, shATG5, and shIBTKα HepG2 cells were treated with palmitate for 24 hours 
and proteasome activity was measured by the chymotrypsin, caspase-like, and trypsin-
like proteasome-glo assays. 
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Figure 5-10. Inhibitors of autophagic flux induce proteasome activation through 
CHOP and NF-κB. (A) HepG2 cells were treated with indicated compounds for 24 hours 
and immunoblot analyses were carried out for indicated proteins. (B) HepG2 cells were 
treated for indicated compounds for 24 hours and proteasome activity was measured by 
the chymotrypsin proteasome-glo assay. (C) WT, CHOP-KO, and RELA-KO cells were 
treated with indicated compounds for 24 hours and cell death was measured by LDH 
release. (D) Wild type, CHOP-KO, and RELA-KO HepG2 cells were treated with 
indicated compounds for 24 hours and proteasome activity was measured by the 
chymotrypsin-like proteasome-glo assay. 
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Figure 5-11. p62 interacts with KEAP1 upon stress treatment that block 
autophagic flux. (A) HepG2 cells were treated for 12 hours with the indicated stress 
compound and cell lysates were used for immunoprecipitation with IGG control (mock) 
or KEAP1, followed by immunoblot analysis.  The left panel measures the indicated 
proteins in total lysates. (B) HepG2 cells were transiently transfected with a plasmid 
containing the coding sequence for p62 and lysates were collected for immunoblot 
analysis for the indicated proteins. (C)  HepG2 cells were transiently transfected with a 
plasmid containing the coding sequence for p62 and proteasome activity was measured 
by chymotrypsin proteasome-glo assay. 
 144 
 
 
5.6  NRF2 enhances cell viability in response to palmitate through proteasome 
activation 
Activation of NRF2 is thought to be a major regulatory mechanism against 
cellular perturbations by inducing gene expression to overcome oxidative damage and 
enhance cellular detoxification [165, 166]. To address the idea the NRF2 is playing a 
protective role due to a block in autophagic flux, we treated both control cells (shCTRL) 
and cells depleted for NRF2 (shNRF2) with vehicle, palmitate, or chloroquine for 24 
hours (Fig 5-12 A-B). Following exposure to palmitate, increased cell death was 
observed in shNRF2 HepG2 cells relative to shCTRL (Fig 5-12 B). Interestingly, p62 and 
LC3b-II were still induced in the NRF2-depleted cells following both treatment regimes, 
whereas proteasome activity was decreased (Fig 5-12 A and E).  
Does NRF2 enhance cell survival through enhanced proteasome activity alone? 
To determine whether the antioxidant potential of NRF2 was playing a protective role 
during palmitate-induced lipotoxicity, we treated shCTRL and shNRF2 cells with 
palmintate alone or in combination with the antioxidant N-acetyl cysteine (NAC), but did 
not observe a significant decrease in cell death in either the shCTRL or shNRF2 cells 
with the addition of NAC (Fig 5-13 A). To investigate the role of the NRF2-mediated 
proteasome response in cell survival, we treated shCTRL and cells depleted for PSMB5 
(shPSMB5), a proteasomal subunit regulated by NRF2 (Fig 5-13 B). Following treatment 
with palmitate for 24 hours, the shPSMB5 HepG2 cells showed increased cell death 
relative to the shCTRL cells (Fig 5-13 B-C). These results suggest that NRF2 is 
mediating cell survival in response to a block in autophagic flux through increased 
proteasome activity as a compensatory mechanism to degrade damaged proteins. 
 145 
 
 
Figure 5-12. NRF2 activation is protective from inhibitors of autophagic flux. (A) 
shCTRL and shNRF2 HepG2 cells were treated with vehicle, chloroquine, or palmitate 
for 12 hours and immunoblots were carried out for indicated proteins. (B) shCTRL and 
shNRF2 cells were treated with palmitate for 24 hours and viability was measure by LDH 
release. (C-D) shCTRL and shNRF2 cells were treated with vehicle, palmitate, or 
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chloroquine for 12 hours and qPCR was carried out on the indicated mRNAs. (E) 
shCTRL and shNRF2 HepG2 cells were treated with vehicle, palmitate, or chloroquine 
for 24 hours and proteasome activity was measured using the chymotrypsin proteo-glo 
assay. 
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Figure 5-13. Proteasome activation is an adaptive response to inhibition of 
autophagic flux by palmitate. (A) shCTRL and shNRF2 HepG2 cells were treated with 
palmitate alone or in the presence of 10mM NAC for 24 hours and cell viability was 
measured by LDH release. (B) shCTRL and shPSMB5 cells were treated with palmitate 
for 24 hours and cell viability was measured by LDH release. (C) shCTRL and shPSMB5 
cells were treated with palmitate or vehicle for 12 hours and immunoblot analyses were 
carried out to measure the levels of the indicated proteins. (D) shCTRL and shPSMB5 
HepG2 cells were treated with either vehicle or palmitate for 24 hours and proteasome 
activity was measured using the chymotrypsin proteasome-glo assay.  
 
 
 148 
 
5.7 Summary 
 Both CHOP and NF-κB have been associated with the progression of NASH, but 
the full extent of biologic pathways which they regulate both hepatocellular injury and 
adaptive responses are not clear [47]. Our study indicates that both CHOP and NF-κB 
regulate the induction of autophagy coordinately through direct promoter binding and 
expression of IBTKα, as well as through the unique binding of essential genes needed to 
form the phagaphore and properly traffic the autophagosome to the lysosome (Fig 5-1 
and 5-5). Additionally, global gene expression analysis revealed that CHOP and NF-κB 
coordinately regulate diverse biological processes in response to palmitate, ranging from 
cell cycle to hepatoceullar survival and inflammation, with approximately 10% of these 
genes being regulated by the transcription factor by their direct binding at the promoters 
of the target genes (Fig 5-4, 5-5, and 5-6). Additionally, CHOP has been shown to be 
essential for phosphorylation of the p65 subunit of NF-κB, which could explain the 
majority of co-regulated gene expression changes observed. A unique biological 
response identified in this study was that both CHOP and NF-κB coordinately regulate 
the proteasome in response to an inhibition of autophagic flux both through NRF2 
activity, which is mediated both by p62 binding to KEAP1. Additionally, CHOP and NF-
κB direct transcriptional expression of NRF2 in response to palmitate treatment, as well 
as through direct binding at genes encoding proteasome subunits (Fig 5-7 and 5-8).  
Further investigations suggest that both the enhanced proteasome activity and NRF2-
mediated response acts as a compensatory mechanism that provides for resistance to a 
block in autophagic flux (Fig 5-10, 5-12, 5-13, and 5-14). These ideas suggest that the 
efficacy of the degradative machinery in the cells and their upstream regulatory networks 
involved are central to the pathogenesis of NASH and progression of hepatocellular 
injury. 
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Figure 5-14. Model for UPR regulation of proteasome activation. Saturated FFAs 
activate PERK and eIF2α~P, which results in preferential translation of CHOP, which is 
required for the phosphorylation of p65 (P~p65). CHOP and P~p65 bind to genes 
involved in both the induction of autophagy, such as IBTKα, as well as the proteasome, 
such as NRF2. Palmitate results in a block in autophagic flux, which causes an 
accumulation of p62. P62 will bind to KEAP1 and prevent KEAP1 from targeting NRF2 
for degradation, allowing for NRF2 to activate proteasome genes such as PSMB5.  
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CHAPTER 6: DISCUSSION 
 
6.1  Saturated FFAs are potent activators of the UPR 
 Saturated FFAs, but not unsaturated FFAs, activate UPR sensory proteins PERK 
and IRE1 prior to lipotoxicity (Fig 3-2) [2, 9, 10]. In fact, unsaturated FFAs can help 
prevent ER stress elicited by palmitate by supporting adaptive mechanisms, including 
activating triglyceride synthesis that can contribute to growth of lipid droplets. There are 
many models for how saturated FFAs can trigger ER stress [9]. We found that a portion 
of palmitate is co-localized to the ER (Fig 3-5), and that saturated FFAs can alter the 
distribution of the lipid droplets (Fig 3-1 and 3-4), which is predominantly synthesized at 
the ER [169]. This suggests that saturated FFAs modify the ER membrane, which 
stresses this organelle [170]. This idea is supported by a study that showed that PERK 
and IRE1 mutants that lacked their ER luminal sensing domains retained their ability to 
be activated upon by increased lipid saturation by a mechanism involving increased 
oligomerization of these UPR sensory proteins [51]. It is curious that expression of the 
UPR sensor ATF6 was not altered in HepG2 cells in response to palmitate (Fig 3-3), and 
it was reported that ATF6 is not activated by cleavage to the mature transcription 
activator [52]. The apparent lack of ATF6 activation may be a consequence of 
differences in the mechanisms by which ER stress is triggered by saturated FFA, as well 
as palmitate alteration of vesicular trafficking required for ATF6 passage to the Golgi for 
cleavage and release to the nucleus. 
 
6.2  CHOP induces secretion of cytokines involved in hepatocyte death and 
inflammation 
 Inflammation plays a critical role in a variety of liver pathologies and activation of 
chronic inflammation may be an important tipping point in the progression from simple 
 151 
 
hepatic steatosis to NASH [11, 22]. Secretion of inflammatory cytokines by resident or 
invading immune cells or release of pro-inflammatory and chemotactic alarmins from 
stressed and dying hepatocytes is suggested to be central to progressive inflammation 
in liver pathology. We propose a novel mechanism through which chronically stressed 
hepatocytes produce cytokines that are part of the cell death and pro-inflammatory 
responses (Fig 3-21). In this model, elevated and sustained CHOP expression is 
considered to be a potent trigger for the UPR to switch from an adaptive function to 
death response [46, 58].  
These experiments suggest that the signaling pathway by which CHOP activates 
NF-κB involves enhanced phosphorylation of p65 phosphorylation at serine 536, which 
is suggested to facilitate nuclear localization and transcriptional activation of NF-κB (Fig 
3-12 and 3-21) [87]. Whereas knockdown of CHOP substantially reduced 
phosphorylation of NF-κB, loss of CHOP function did not deter lowered IκBα levels 
during treatment with palmitate. Translational expression of IκBα is substantially reduced 
upon PERK phosphorylation of eIF2α~P [148]; therefore there are multiple modes of 
UPR regulation of NF-κB. It is noteworthy than knockdown of RELA (p65) did not 
diminish enhanced CHOP expression by palmitate (Fig 3-14), which supports the idea 
that CHOP functions upstream of NF-κB to induce expression of cytokines. Part of 
CHOP activation of NF-κB involves the IRAK2 protein kinase, which directly or indirectly 
enhances p65 phosphorylation at serine 536 (Fig 3-15). It was reported that both CHOP 
and NF-κB can bind to the CXCL8 (IL-8) gene promoter in stressed human bronchial 
epithelial cells, suggesting that CHOP may also contribute directly to transcriptional 
activation of cytokine gene expression [171]. 
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6.3 The UPR and inhibition of autophagic flux is a key driver of NASH 
Autophagy is often thought of as a cell survival pathway that directs damaged 
organelles and misfolded proteins for degradation in lysosomes [172]. However, 
autophagy can also play a direct role in cell death, and recent studies have suggested 
that there are two main processes: (1) type II autophagic cell death, which consists of 
cell death accompanied by accumulation of large secondary vacuoles, and (2) autosis, 
which is characterized by a disappearance of the ER and general self-eating [173]. Our 
studies suggest that saturated FFAs induce neither type II cell death nor autosis, as 
autophagy is a key driver in hepatocellular death without the appearance of secondary 
lysosomes (Fig 4-7 and 4-11). A key feature of our study is the localization of IBTKα to 
ERES through a complex that includes LC3b, SEC16A, and SEC31A (Fig 4-14). When 
the hepatocytes were exposed to palmitate, LC3b-II was retained at the ER with IBTKα, 
suggesting either a defect in phagophore elongation or trafficking from the ERES to the 
lysosome. These findings suggest that saturated FFAs induce a novel form of 
autophagic cell death, perhaps a subset of autosis, which allows for the lipidation of 
LC3b but interferes with LC3b trafficking from the ER to lysosomes. Importantly, this 
block in autophagic flux is coincident with increased inflammation and TNFα signaling, 
thereby linking key features of NASH pathogenesis in a linked signaling cascade (Fig 4-
21).  While it is possible that this form of cell death is unique to metabolic stress, it is 
also likely to be a driver in other diseases states or even drug-induced liver injury in 
which hepatocellular death and inflammation or prominent pathologies. 
Induction of the UPR and a block in autophagic flux were also supported by our 
analysis of human liver biopsy samples, which indicated that levels of IBTKα and CHOP, 
as well as total and phosphorylated P65 were increased in both simple steatosis and in 
NASH (Fig 4-18). Importantly, levels of LC3b-II and P62 were significantly elevated in 
NASH, which were strongly associated with hepatocellular injury markers, such as 
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ballooning. Therefore, we identified biomarkers suggested to be specific for NASH, as 
well as others associated with general NAFLD.  Furthermore, analyses of the liver 
biopsy samples indicate that our in vitro model correlates well with the events occurring 
in NAFLD. Our principal component analysis combining protein quantification, histology, 
and serum analysis indicates that key factors and pathways described herein will provide 
new insight into the progression of simple steatosis to NASH.   
In summary, we identified IBTKα as a new member of the UPR that is 
transcriptionally and translationally expressed during metabolic stress. IBTKα plays a 
role in both phagophore initiation and formation of transport vesicles at the ERES, linking 
autophagy and secretion to the pathogensis of NASH.  Furthermore, our study indicates 
that aberrant autophagy and the consequent inhibition of autophagic flux is a key driver 
in the pathogensis of NASH at both the cellular level and as a correlative biomarker in 
patient samples. At present, no approved therapies exist to treat NASH, and there is a 
need for better mechanistic understanding of cellular targets that repress the associated 
pathologies and progression of NASH. The ability to target both hepatocellular death and 
inflammation through IBTKα in the treatment in simple steatosis and/or NASH could 
have therapeutic benefit, and further work in the validation of this target is warranted. 
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Figure 6-1. The UPR in hepatocellular autophagy and inflammation. Model 
describing the roles of activation UPR and key transcription factors in the pathogenesis 
of NASH. 
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6.4  CHOP and NF-κB coordinately regulate gene expression  
Both inhibition of autophagic flux and hepatocellular inflammation, such as the 
secretion of TNFα, are key drivers in the lipotoxicity associated with palmitate. Our 
studies indicate that not only is CHOP required for phosphorylation of p65, but that 
CHOP and NF-κB coordinately regulate global gene expression responses in 
hepatocytes (Fig 3-12, 5-4, and 5-6). Furthermore, we found that although CHOP and 
NF-κB result in the co-regulation of global gene expression, many biological pathways 
are controlled by direct promoter binding of only ~10% of those genes induced or 
repressed following palmitate exposure. This finding suggests that CHOP and NF-κB 
regulate discrete nodes in gene expression networks, which together have large scale 
effects on the global transcriptome and consequent biological expression. 
A key feature of NASH is inhibition of autophagic flux, which we determined 
triggers activation of the proteasome through NRF2 (Fig 5-7). CHOP and NF-κB 
contribute to increased NRF2 expression in hepatocytes treated with palmitate. 
Additionally, we suggest that inhibition of autophagic flux results in an accumulation of 
p62, which binds to KEAP1, resulting in NRF2 nuclear localization and enhanced 
expression gene encoding proteasome subunits, such as PSMB5 (Fig 5-7 and 5-8). 
Additionally, we showed that enhanced proteasome activity was an adaptive response to 
inhibition of autophagic flux in hepatocytes. These investigations suggest that although 
depletion of CHOP and NF-κB is cytoprotective in response to palmitate exposure, these 
transcription factors play dynamic roles to co-regulate biological processes that 
participate in both pro-death and pro-survival depending on the context and timing of the 
ER stress conditions. 
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6.5 UPR in NASH and model systems 
Studies on rodent dietary models of NASH and inflammation suggest distinct 
differences from humans [142, 143]. Our results suggest that there are critical signaling 
differences in the hepatocyte from these different species (Fig 3-21). Whereas both 
human and mouse hepatocytes showed induction of the UPR and CHOP expression in 
response to saturated FFA, only human liver cells showed activation of NF-κB and 
increased expression of key cytokines, such as TNFα, which triggered cell death and 
inflammation. An underlying contributor to human CHOP activation of NF-κB is p65 
phosphorylation at serine-536 by a signaling pathway featuring IRAK2. In mouse primary 
hepatocytes, there was no induction of p65 phosphorylation in response to palmitate and 
there was minimal IRAK2 expression (Fig 3-18). Furthermore, expression of TNFα and 
murine homologue KC were not significantly elevated in mouse cells treated with 
saturated FFA as observed in human hepatocytes (Fig 3-18). Rodent models of NASH 
are often lacking in their ability to mimic the human disease [142, 143]. These results 
suggest that phenotypic deficiencies of mouse dietary models of NASH are due to the 
absence of key portions of UPR signaling through IRAK2/NF-κB, resulting in lowered 
hepatotoxicity and macrophage recruitment in response saturated FFA. 
Interestingly, both rodent models of NASH and human liver biopsy samples from 
patients with NASH exhibit UPR induction preceding inhibition of autophagic flux, 
suggesting a strong correlation between these biological pathways and liver injury [50, 
174, 175]. Furthermore, addition of recombinant TNFα in the presence of palmitate to 
HepG2 cells depleted for IBTKα and CHOP resulted in cell death, but not to the full 
extent of wild type cells, which have the autophagic pathway intact (Fig 4-17). These 
results suggest that both an inhibition and autophagic flux and the secretion of CHOP-
dependent secreted factors, such as TNFα, are required for lipotoxicity during the 
pathogensis of NASH. We showed that IBTKα not only plays a role in both the induction 
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of autophagy, but also the formation of COPII vesicles and consequent secretion of 
cytokines such as TNFα (Fig 4-11 and 4-17). Furthermore, IBTKα is upregulated in 
NASH patients coincident with an inhibition of autophagic flux and secretion of TNFα 
(Fig 4-18 and 4-19), suggesting that depletion of this CHOP-dependent factor could 
have therapeutic potential to alleviate both hepatoxicity and inflammation observed in 
NASH. 
In summary, we describe new mechanisms that link chronic activation of the 
UPR with cell death and inflammation, two critical components of progression from 
hepatic steatosis to NASH. While it is well known that liver-related complications due to 
NASH are on the rise, there are no FDA approved therapeutic interventions to control 
the progression of NAFLD to NASH. Furthermore, there is a need for improved 
prognostic biomarkers and an understanding of genetic susceptibility to NASH. It is 
noteworthy that there are genetic polymorphisms in IRAK2 that significantly alter NF-κB 
activation [150-153], and our study suggests that these genetic alterations will alter 
CHOP signaling in response to saturated FFA and will affect induction of secreted 
factors in hepatocytes that trigger inflammation and death. UPR signaling events will 
also offer new strategies for the diagnosis and treatment of NASH. 
 
6.6 Biomarkers for monitoring the pathogenesis of NAFLD 
 While the current standard for differentiating patients with simple steatosis from 
non-alcoholic steatohepatitis involves the characterization of liver biopsy samples, there 
is a great need for the development of non-invasive biomarkers to assess NAFLD 
progression [176]. Currently, physicians suggest that there are two key transitions in 
which biomarkers would be helpful for diagnosis of liver pathologies: (1) simple steatosis 
from NASH and (2) the onset of fibrosis. Recent studies have suggested that biomarkers 
that predict hepatocelluar death, such as caspase cleaved cytokeratin 18, and 
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inflammation, such as TNFα and adipokines, may be useful to differentiate NASH from 
simple steatosis [177, 178]. Our results indicate that CHOP regulates the secretion of 
cytokines such as TNFα and IL-8 through both the expression of IBTKα and consequent 
activation of NF-κB (Fig 4-21). While we did not look for the expression of and release of 
novel biomarkers of cellular injury and inflammation due to palmitate exposure, we did 
see a global reduction in secretion due to repression of IBTKα coincident with a 
reduction in palmitate-induced cell death in IBTKα depleted HepG2 cells (Fig 4-9 and 4-
17), suggesting that the CHOP-IBTKα pathway is responsible for the secretion of other 
biomarkers involved in NASH.  
 Although the vast majority of publications in the field focus on discovering non-
invasive biomarkers to monitor the onset of NASH and fibrosis, the identification of 
biomarkers which appropriately identifies obese individuals with and without simple 
steasosis would be of significant value. Our principle component analysis revealed that 
we have a robust in vitro assay in correlation with in vivo NASH, but few markers 
correlated with simple steatosis alone (Fig 4-20). In order to better monitor the 
progression of NAFLD in the clinic, including the potential reversibility, it will be 
necessary to both develop robust models and identify biomarkers for simple steatosis. 
 
6.7 Therapeutic landscape for NASH 
 Currently the standard of care for reversal of both simple steatosis and NASH is 
lifestyle modifications, including caloric restriction and exercise, and sometimes the need 
for bariatric surgery or liver transplantation in severe cases of liver disease. While the 
current belief is that pharmacological intervention is not necessary for the reversal of 
simple steatosis, there is growing consensus that patients with NASH can benefit from 
pharmaceutical intervention [179]. Unfortunately, there are currently no FDA-approved 
therapies for NASH, although pharmacologic agents have been investigated pre-
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clinically focus on weight loss, decreased lipid accumulation, as well as enhanced insulin 
sensitivity. However, the clinical relevance and efficacy of many of these biological 
targets have not yet been fully tested [180, 181]. Our studies indicate that inhibition of 
autophagic flux coincident and the consequent secretion of TNFα is a key molecular 
event driving hepatocellular injury during the pathogenesis of NASH both in vitro and in 
human liver biopsy samples. Furthermore, both the UPR and NF-κB regulate the 
induction of autophagy and secretion of cytokines through IBTKα (Fig 4-18 and 5-1). 
Inhibition of the induction of autophagy reduces the secretion of TNFα and rescues 
hepatocytes from palmitate-induced lipotoxicity, suggesting that this pathway might be a 
viable therapeutic target for NASH. 
 
6.8  Closing remarks 
 The UPR and inhibition of autophagic flux have been associated with NASH in 
both rodent and human liver biopsy samples, and a major goal of this investigation was 
to establish the role of the UPR in the pathogenesis of NASH through mechanistic 
studies using human hepatocytes. We show that palmitate directly localizes to the ER 
wherein it can activate PERK, resulting in activation of the UPR and eIF2α~P, which 
induces CHOP expression. Deletion of CHOP not only prevented the induction of 
autophagy and palmitate-induced lipotoxicity, but also prevented phosphorylation and 
nuclear localization of the p65 subunit of NF-κB, and consequent secretion of cytokines, 
such as TNFα and IL-8. The idea that CHOP regulates NF-κB and secretion is a new 
concept with regards to UPR signaling. While we present insight about the coordinated 
regulation of secreted biomarkers by CHOP and NF-κB following hepatoceullar 
lipotoxicity, the full extent of how the secretome is modified is an important topic for 
future study. Additionally, a better understanding of how CHOP and NF-κB regulate 
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global secretion in response to lipotoxicity, including the extracellular release of lipids 
and non-coding RNAs, will be important for the development of future sera-based 
biomarkers for NASH. 
While the idea that inhibition of autophagic flux has been associated with NASH 
[50], we showed that a block in autophagic flux is a key driver in the hepatocellular injury 
during lipotoxicity, providing insight into the intracellular pathway regulating cell injury 
during the pathogenesis of NASH.  Furthermore, we identified IBTKα as a novel UPR 
member that is essential for inducing autophagy through the formation of a multi-subunit 
complex at the ERES. Not only is IBTKα essential for the induction of autophagy, but we 
also showed that IBTKα is critical for secretion of cytokines, such as TNFα. Because 
NASH is associated with both an inhibition of autophagic flux and hepatocellular 
inflammation, the ability to target a biological node responsible for both adverse 
pathways could prove the most beneficial. 
 A final goal of this investigation was to utilize next generation sequencing to 
understand the extent of co-regulated networks by CHOP and NF-κB following 
lipotoxicity. We found that both CHOP and NF-κB coordinately regulate global gene 
expression, and that each transcription factor binds to a subset of promoters to control 
critical biological networks, such as inflammation and autophagy. Furthermore, we 
discovered that in response to an inhibition of autophagic flux, hepatocytes enhance 
proteasome activity through NRF2 activity, through a pathway involving both CHOP and 
NF-κB.  The utility of an NRF2 activator for the treatment of NASH remains questionable. 
Although activation of proteasomes would presumably enhance the ability of the 
hepatocyte to degrade misfolded proteins, the proteasome is incapable of degrading 
damaged organelles, such as the ER and mitochondria. Similarly, long-term inhibition of 
autophagy through inhibiting IBTKα might provide a short-term survival advantage, but 
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might not be a feasible target for a chronic disease state as cells rely upon autophagy for 
survival. Hence, a greater understanding of networks regulated by CHOP and NF-κB in 
response to palmitate will be essential to fully appreciate the impact of the UPR with 
regards to cell injury and potential therapeutic benefit for NAFLD. 
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Appendix 1. Top 350 proteins identified in pull-downs with IBTKα by using mass 
spectrometry and MudPIT. 
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Appendix 2. List of CHOP and P~p65 target genes that have binding peaks  
near TSS of annotated gene. 
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Appendix 3. List of top 450 induced genes following palmitate  
treatment identified through RNA-seq. 
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Appendix 4. List of top 450 repressed genes following palmitate  
treatment identified through RNA-seq. 
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